EP4281048A1 - Prolonged-release furazidin composition - Google Patents
Prolonged-release furazidin compositionInfo
- Publication number
- EP4281048A1 EP4281048A1 EP22702430.4A EP22702430A EP4281048A1 EP 4281048 A1 EP4281048 A1 EP 4281048A1 EP 22702430 A EP22702430 A EP 22702430A EP 4281048 A1 EP4281048 A1 EP 4281048A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- furazidin
- pharmaceutical composition
- release component
- modified
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DECBQELQORZLLP-UAIOPKHMSA-N 1-[(e)-[(e)-3-(5-nitrofuran-2-yl)prop-2-enylidene]amino]imidazolidine-2,4-dione Chemical compound O1C([N+](=O)[O-])=CC=C1\C=C\C=N\N1C(=O)NC(=O)C1 DECBQELQORZLLP-UAIOPKHMSA-N 0.000 title claims abstract description 228
- 229960002375 furazidin Drugs 0.000 title claims abstract description 226
- 230000002035 prolonged effect Effects 0.000 title claims abstract description 51
- 239000000203 mixture Substances 0.000 title description 50
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 169
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims abstract description 162
- 208000019206 urinary tract infection Diseases 0.000 claims abstract description 52
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 40
- 238000013270 controlled release Methods 0.000 claims abstract description 37
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 33
- 239000011230 binding agent Substances 0.000 claims description 58
- 239000000314 lubricant Substances 0.000 claims description 51
- 239000000945 filler Substances 0.000 claims description 49
- 239000002552 dosage form Substances 0.000 claims description 46
- 239000007884 disintegrant Substances 0.000 claims description 44
- 229920000642 polymer Polymers 0.000 claims description 39
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 37
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 37
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 37
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 35
- 238000004090 dissolution Methods 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 33
- 239000008187 granular material Substances 0.000 claims description 32
- 230000036470 plasma concentration Effects 0.000 claims description 31
- 239000011159 matrix material Substances 0.000 claims description 26
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 26
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 23
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 23
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 22
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 18
- 229920000609 methyl cellulose Polymers 0.000 claims description 18
- 235000010981 methylcellulose Nutrition 0.000 claims description 18
- 238000000338 in vitro Methods 0.000 claims description 17
- 239000001923 methylcellulose Substances 0.000 claims description 17
- -1 poly(ethylene oxide) Polymers 0.000 claims description 14
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 12
- 229920001531 copovidone Polymers 0.000 claims description 12
- 230000002745 absorbent Effects 0.000 claims description 11
- 239000002250 absorbent Substances 0.000 claims description 11
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 10
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 10
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 10
- 239000008055 phosphate buffer solution Substances 0.000 claims description 9
- 230000001154 acute effect Effects 0.000 claims description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 8
- 230000000306 recurrent effect Effects 0.000 claims description 8
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 6
- 229920001577 copolymer Polymers 0.000 claims description 6
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 6
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 6
- 239000000230 xanthan gum Substances 0.000 claims description 6
- 229920001285 xanthan gum Polymers 0.000 claims description 6
- 235000010493 xanthan gum Nutrition 0.000 claims description 6
- 229940082509 xanthan gum Drugs 0.000 claims description 6
- 235000012054 meals Nutrition 0.000 description 62
- 210000002700 urine Anatomy 0.000 description 40
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 26
- 229940079593 drug Drugs 0.000 description 25
- 239000003814 drug Substances 0.000 description 25
- 238000012360 testing method Methods 0.000 description 24
- 230000029142 excretion Effects 0.000 description 22
- 239000000047 product Substances 0.000 description 21
- 230000008961 swelling Effects 0.000 description 21
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical class [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- 229920002261 Corn starch Polymers 0.000 description 15
- 235000019759 Maize starch Nutrition 0.000 description 15
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 15
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 15
- 239000008108 microcrystalline cellulose Substances 0.000 description 15
- 229940016286 microcrystalline cellulose Drugs 0.000 description 15
- 238000002156 mixing Methods 0.000 description 14
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 14
- 238000005550 wet granulation Methods 0.000 description 14
- 235000020937 fasting conditions Nutrition 0.000 description 13
- 238000009472 formulation Methods 0.000 description 11
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 10
- 235000021355 Stearic acid Nutrition 0.000 description 10
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 10
- 238000007908 dry granulation Methods 0.000 description 10
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 10
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 10
- 239000008363 phosphate buffer Substances 0.000 description 10
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 10
- 238000005070 sampling Methods 0.000 description 10
- 239000000377 silicon dioxide Substances 0.000 description 10
- 229920003109 sodium starch glycolate Polymers 0.000 description 10
- 239000008109 sodium starch glycolate Substances 0.000 description 10
- 229940079832 sodium starch glycolate Drugs 0.000 description 10
- 239000008117 stearic acid Substances 0.000 description 10
- 230000002411 adverse Effects 0.000 description 9
- 230000008030 elimination Effects 0.000 description 9
- 238000003379 elimination reaction Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 230000036325 urinary excretion Effects 0.000 description 9
- 235000021152 breakfast Nutrition 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 102220487426 Actin-related protein 2/3 complex subunit 3_K15M_mutation Human genes 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000004513 sizing Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 230000009246 food effect Effects 0.000 description 6
- 235000021471 food effect Nutrition 0.000 description 6
- 229960001021 lactose monohydrate Drugs 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 210000000813 small intestine Anatomy 0.000 description 5
- 229960004793 sucrose Drugs 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 229920003083 Kollidon® VA64 Polymers 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 229920000881 Modified starch Polymers 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 235000019482 Palm oil Nutrition 0.000 description 4
- 229920003072 Plasdone™ povidone Polymers 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 229960001681 croscarmellose sodium Drugs 0.000 description 4
- FYUWIEKAVLOHSE-UHFFFAOYSA-N ethenyl acetate;1-ethenylpyrrolidin-2-one Chemical compound CC(=O)OC=C.C=CN1CCCC1=O FYUWIEKAVLOHSE-UHFFFAOYSA-N 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 229960001375 lactose Drugs 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 150000004682 monohydrates Chemical class 0.000 description 4
- 239000002540 palm oil Chemical class 0.000 description 4
- 229940069328 povidone Drugs 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical class CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 4
- 210000001635 urinary tract Anatomy 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 201000003146 cystitis Diseases 0.000 description 3
- 235000013681 dietary sucrose Nutrition 0.000 description 3
- 229940126534 drug product Drugs 0.000 description 3
- 229940088679 drug related substance Drugs 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 238000010579 first pass effect Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000009490 roller compaction Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000009491 slugging Methods 0.000 description 3
- 210000003708 urethra Anatomy 0.000 description 3
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 2
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 2
- 206010056396 Asymptomatic bacteriuria Diseases 0.000 description 2
- 208000037041 Community-Acquired Infections Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000237858 Gastropoda Species 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 206010037596 Pyelonephritis Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 239000008116 calcium stearate Chemical class 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229940047766 co-trimoxazole Drugs 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical class CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229910021485 fumed silica Inorganic materials 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 208000024798 heartburn Diseases 0.000 description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 150000003248 quinolines Chemical class 0.000 description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 201000004538 Bacteriuria Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 206010071445 Bladder outlet obstruction Diseases 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 208000002513 Flank pain Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010027566 Micturition urgency Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 208000008718 Pyuria Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010050822 Suprapubic pain Diseases 0.000 description 1
- 208000003800 Urinary Bladder Neck Obstruction Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 231100000987 absorbed dose Toxicity 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 201000005661 acute cystitis Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000009506 drug dissolution testing Methods 0.000 description 1
- 238000009112 empiric therapy Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000009477 fluid bed granulation Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229960000308 fosfomycin Drugs 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 238000009478 high shear granulation Methods 0.000 description 1
- 239000012728 immediate-release (IR) tablet Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000009476 low shear granulation Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 235000021134 protein-rich food Nutrition 0.000 description 1
- 208000024981 pyrosis Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 206010038464 renal hypertension Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 208000022934 urinary frequency Diseases 0.000 description 1
- 230000036318 urination frequency Effects 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- the present invention relates to a prolonged-release pharmaceutical composition of furazidin for oral administration, which can be used for treating urinary tract infections (UTI).
- UTI urinary tract infections
- Urinary tract infections are the most common condition requiring medical consultation and care in outpatients. UTIs account for approx. 10-20% of all community- acquired infections and for approx. 40-50% of nosocomial infections. Approx. 80% of all UTIs occur in women. According to epidemiological studies, bacteriuria occurs at least once in a lifetime of approx. 10% of female population and in 1-2% of male population, with asymptomatic UTIs in women probably occurring twice as frequently.
- UTI urinary tract infection
- cUTI complex UTI
- UTI is classified as uncomplicated if there are no relevant functional or anatomical anomalies in the urinary tract, no relevant renal functional impairment and no relevant concomitant disease that would promote the UTI, or the risk of developing serious complications.
- uncomplicated UTI include:
- AUC Acute uncomplicated cystitis
- Acute uncomplicated pyelonephritis An upper UTI (pyelonephritis) ought to be assumed if, in the case of acute symptoms, flank pain, pain on palpation of the flank, and/or fever (>38°C) persist.
- Asymptomatic bacteriuria Clinically symptomatic UTI is distinguished from asymptomatic bacteriuria. The term ‘asymptomatic UTI’ ought not to be used.
- Recurrent uncomplicated UTIs A recurrent UTI is assumed if relapse rates of >2 symptomatic episodes occur within 6 months or >3 symptomatic episodes within 12 months.
- UTIs are a significant clinical problem due to their serious sequelae, such as septic conditions, urolithiasis, renal failure, hypertension or occurrence of these complications during pregnancy.
- Community-acquired infections most often occur as a result of ascending invasion of native bacterial flora coming from the gastrointestinal tract.
- the first stage of infection is colonisation of the urinary meatus (in males; in females, the vestibule of the vagina), followed by urinary bladder invasion through the urethra.
- Recurrent UTIs are defined as infections characterised by at least 3 episodes within one year or 2 episodes within 6 months. Infection recurrence is understood as a repeated UTI episode caused by the same micro-organism, i.e. by its endospores, within 3 weeks of the end of treatment. Such recurrences are often asymptomatic. Reinfections are repeated infections occurring after the urinary tract has been sterilised using antibacterial agents, but caused by a different bacterial strain, occurring up to 14 days after sterilisation of urine. In the population of young, healthy and sexually active women, 10% experience at least one UTI episode a year, and the risk of recurrent UTIs is approx. 0.5- 0.7/person/year.
- furazidin is efficient in the treatment of different forms of UTI. It is also safe, exhibiting less side effects, comparing to other antimicrobial agents and may be administered to children as well.
- the efficacy results from the high sensitivity of micro-organisms to furazidin.
- the low resistance of uropathogens to furazidin is virtually unchanging in time, contrary to what is observed in the case of other antibiotics or chemotherapeutic agents.
- Escherichia coli the most frequent pathogen causing acute UTIs (70-95% of cases), is susceptible to furazidin at a constant level of approx.
- furazidin upon oral administration, furazidin has a very short half-life (below 1 hour). Blood drug concentrations of furazidin decrease very quickly after administration, reaching levels lower than the minimum concentration for exhibiting therapeutic effects. This creates a necessity of frequent administration of furazidin, which is according to the prior art administered in the form of immediate release (IR) tablets, containing 50 or 100 mg of furazidin. Due to the unfavourable pharmacokinetics, furazidin must be administered 3 to 4 times daily (each time 100 mg or 2 x 50 mg of furazidin) in order to maintain an effective concentration of furazidin in the plasma.
- IR immediate release
- furazidin is quickly absorbed in the gastrointestinal tract, reaching high blood concentrations. During this time, intensive liver metabolism occurs, causing exacerbation of adverse effects.
- the present invention relates to the following aspects:
- a prolonged-release pharmaceutical composition for oral administration comprising: a) an immediate release component, comprising furazidin and one or more pharmaceutically acceptable excipients; and b) a modified-release component, comprising furazidin, a controlled-release agent, and one or more pharmaceutically acceptable excipients.
- composition according to (1) or (2) wherein the pharmaceutical composition is a single dosage form in the form of a tablet, in which the immediate release component a) forms a first layer, the modified-release component b) forms a second layer, and the first layer at least partially covers the surface of the second layer.
- the tablet is a bilayer tablet.
- the immediate release component a) and/or the modified- release component b) also contain an extragranular fraction, for example, comprising one or more of a lubricant, a filler, an absorbent and a glidant.
- the immediate release component a) has a furazidin content of 32 to 50 wt.%, preferably 41 to 50 wt.%, more preferably 45 to 46 wt.%, such as 45.45 wt.%, based on the total weight of the immediate release component a); furthermore, the modified release component b) has a furazidin content of 40 to 60 wt.%, preferably 52 to 56 wt.%, more preferably 54 to 55 wt.%, such as 53.57 wt.%, based on the total weight of the modified-release component b).
- modified-release component b) comprises 10 to 40 wt.% of the controlled-release agent, preferably 10 to 35 wt.% and more preferably 20 to 30 wt.% of the controlled-release agent, based on the total weight of the modified-release component b).
- the controlled-release agent comprises at least one pH- independent polymer.
- the matrix is formed by the pH-independent polymer, or by the pH-independent polymer and a binder.
- a thickness ratio of the thickness of the matrix of the pH-independent polymer in a swollen state to the thickness of the dry matrix of the pH-independent polymer before swelling is in the range of 1.1 to 1.8, preferably 1.3 to 1.6, at each pH of 1.2, 4.5, 6.8 and 7.4, wherein the swollen state is obtained by immersing the dry modified release component b) in 30 to 35 mL of a solution contained in a beaker for 2 h, the beaker being placed in a wiggled, heated bath at 37°C, the solution being a phosphate buffer of pH 4.5, 6.8 or 7.4 or aqueous HC1 of pH 1.2.
- HPMC hydroxypropylmethylcellulose
- HEC hydroxyethylcellulose
- MC methylcellulose
- xanthan gum sodium carboxymethylcellulose
- copovidone vinylpyrrolidone-vinyl acetate copolymer
- Preferred examples of hydroxypropylmethylcellulose (HPMC) have a weight average molecular weight (Mw) of 70,000 to 1,000,000, preferably 70,000 to 600,000, more preferably 70,000 to 170,000.
- Preferred examples of carboxymethylcellulose (CMC) have a weight average molecular weight of 200,000 to 500,000, preferably 350,000 to 450,000, more preferably 370,000 to 400,000.
- Preferred examples of hydroxyethylcellulose (HEC) have a weight average molecular weight of 50,000 to 200,000, preferably 80,000 to 150,000, more preferably 80,000 to 100,000.
- methylcellulose have a weight average molecular weight of 12,000 to 280,000, preferably 10,000 to 220,000, more preferably 370,000 to 400,000.
- Preferred examples of copovidone have a weight average molecular weight of 50,000 to 100,000, preferably 45,000 to 70,000.
- hydroxypropylmethylcellulose KI 5M a combination of hydroxypropylmethylcellulose KI 5M and copovidone (e.g. Kollidon VA 64 and/or Plasdone S 630).
- the pH-independent polymer is a combination of hydroxypropylmethylcellulose K4M and hydroxy ethylcellulose.
- the immediate release component a) comprises, as the at least one excipient, at least one of a filler, a disintegrant, a binder, a lubricant, a glidant and any combination thereof.
- the immediate release component a) comprises a filler, a disintegrant, a glidant, a lubricant, and, optionally, a binder.
- the immediate release component a) contains a binder in addition to the filler, the disintegrant, the glidant and the lubricant.
- modified-release component b) comprises, as the at least one excipient, at least one of a filler, a disintegrant, a binder, a lubricant, a glidant and any combination thereof.
- the modified-release component b) comprises a filler, a disintegrant, a binder, a lubricant, and, optionally, a glidant. More preferably, the modified-release component b) contains no glidant.
- the filler is at least one independently selected from the group consisting of anhydrous or monohydrate lactose, sucrose, microcrystalline cellulose, starch such as maize starch, pregelatinized starch, microcrystalline cellulose coated with colloidal silica, mannitol and any combination thereof, preferably the filler is at least one independently selected from the group consisting of anhydrous or monohydrate lactose, mannitol, microcrystalline cellulose, maize starch, saccharose and any combination thereof, and more preferably the filler is at least one selected from the group consisting of lactose monohydrate, microcrystalline cellulose, or a combination thereof.
- the binder is at least one independently selected from the group consisting of hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, carboxymethylcellulose, hydroxycellulose, hydroxyethylcellulose, polyvinyl alcohol, polyvinylpyrrolidone, copovidone, pregelatinized starch, gelatine and any combination thereof, preferably the binder is at least one independently selected from the group consisting of hydroxypropyl cellulose, polyvinylpyrrolidone and any combination thereof, and more preferably the binder is polyvinylpyrrolidone.
- the disintegrant is at least one independently selected from the group consisting of carboxymethylcellulose sodium salt, sodium croscarmellose, microcrystalline cellulose, crospovidone, sodium starch glycolate, maize starch, and any combination thereof, preferably the disintegrant is at least one independently selected from the group consisting of sodium starch glycolate, sodium croscarmellose, maize starch and any combination thereof, more preferably the disintegrant is sodium croscarmellose or sodium starch glycolate.
- the lubricant is at least one independently selected from the group consisting of stearic acid, magnesium stearate, calcium stearate, sodium stearyl fumarate, glycerol tri stearate, palm oil derivatives such as palmitic acid or hydrogenated palm oil, hydrogenated vegetable oil, such as hydrogenated castor oil, and any combination thereof, preferably the lubricant is at least one independently selected from magnesium stearate and stearic acid.
- the immediate release component a) but not the modified-release component b) comprises a glidant.
- the glidant is at least one independently selected from the group consisting of fumed silica (colloidal silicon dioxide), such as colloidal anhydrous silica, starch, talc and any combination thereof, preferably the glidant is colloidal anhydrous silica.
- the immediate release component a) comprises 10 to 50 wt.%, preferably 10 to 30 wt.%, of a filler, 0.5 to 6 wt.%, preferably 2 to 6 wt.%, of a disintegrant, 1.4 to 1.7 wt.%, preferably 1.6 wt.%, of a glidant, 2 to 4 wt.%, preferably 2.3 wt.%, of a lubricant, based on the total weight of the immediate release component a).
- the modified-release component b) comprises 10 to 40 wt.%, preferably 10 to 35 wt.%, more preferably 20 to 30 wt.%, of the controlled-release agent, 10 to 45 wt.%, preferably 10 to 30 wt.%, of a filler, 0.3 to 5 wt.%, preferably 2 to 5 wt.%, more preferably 3 wt.%, of a disintegrant, 0.4 to 5 wt.%, preferably 0.9 wt.%, of a binder, 0.5 to 2 wt.%, preferably 1 wt.%, of a lubricant, and, optionally, up to 1.3 wt.% of a glidant and preferably no glidant, based on the total weight of the modified-release component b).
- the immediate release component a) contains 45.5 wt.% of furazidin, 29.5 wt.% of microcrystalline cellulose, 5.0 wt.% of sodium starch glycolate, 15.6 wt.% of maize starch, 1.6 wt.% of colloidal anhydrous silica, 2.3 wt.% of stearic acid and 0.5 wt.% of polyvinylpyrrolidone, based on the total weight of the immediate release component a).
- modified-release component b) contains 53.6 wt.% of furazidin, 13.6 wt.% of lactose monohydrate, 19.7 wt.% of hydroxypropylmethylcellulose K4M, 8.2 wt.% of hydroxy ethylcellulose, 3 wt.% of croscarmellose sodium, 1.0 wt.% of magnesium stearate and 0.9 wt.% of polyvinylpyrrolidone, based on the total weight of the immediate release component b).
- composition according to any one of (1) to (36), wherein the pharmaceutical composition is a single dosage form and configured to provide, after oral administration, a maximum plasma concentration of furazidin (Cmax) of 353.1 ⁇ 122.5 ng/mL after tmax of 2.5 ⁇ 0.5 hours after administration, and an area under the plasma concentrationtime curve from time zero to 24 hours (AUC0-24) of 1404.1 ⁇ 392.8 ng h/mL, as determined by human PK studies.
- Cmax maximum plasma concentration of furazidin
- AUC0-24 area under the plasma concentrationtime curve from time zero to 24 hours
- composition according to any one of (1) to (37), wherein the pharmaceutical composition is configured to provide, after oral administration of a single dosage form of the pharmaceutical composition twice a day and 12 hours apart for 3 days, a maximum plasma concentration in steady state (C ma x,ss) of furazidin of 516.4 ⁇ 149.3 ng/mL and an area under the plasma concentration-time curve from time zero to 24 hours in steady state (AUCO-24,SS) of 3498.1 ⁇ 932.2 ng h/mL, as determined by human PK studies.
- C ma x,ss maximum plasma concentration in steady state
- AUCO-24,SS area under the plasma concentration-time curve from time zero to 24 hours in steady state
- CTAB hexadecyltrimethylammonium bromide
- the present invention relates to a pharmaceutical composition as defined in any one of (1) to (39) for use in a method of treatment of a urinary tract infection.
- the pharmaceutical composition for use according to (40), wherein the urinary tract infection is an acute or recurrent uncomplicated urinary tract infection, such as infections in women caused by Escherichia coli.
- composition for use according to any one of (40) to (42), wherein the pharmaceutical composition is a single dosage form, which is administered orally within an interval of from 30 min before a meal and 30 min after a meal, preferably between at a meal and 30 min after a meal.
- composition for use according to any one of (40) to (44), wherein oral administration of one single dosage form of the pharmaceutical composition provides a maximum plasma concentration of furazidin (Cmax) of 353.1 ⁇ 122.5 ng/mL after tmax of 2.5 ⁇ 0.5 hours after administration, and an area under the plasma concentration-time curve from time zero to 24 hours (AUC0-24) of 1404.1 ⁇ 392.8 ng h/mL, as determined by human PK studies.
- Cmax maximum plasma concentration of furazidin
- AUC0-24 area under the plasma concentration-time curve from time zero to 24 hours
- the prolonged-release pharmaceutical composition for oral administration has the features according to the above (1) and (3).
- a the prolonged-release pharmaceutical composition for oral administration which comprises: a) an immediate release component, comprising furazidin and one or more pharmaceutically acceptable excipients; and b) a modified-release component, comprising furazidin, a controlled-release agent, and one or more pharmaceutically acceptable excipients, wherein the pharmaceutical composition is a single dosage form in the form of a bilayer tablet, in which the immediate release component a) forms a first layer, the modified- release component b) forms a second layer.
- the pharmaceutical composition for oral administration according to this aspect may be further characterized according to any one of the above (2) and (4) to (39).
- the said pharmaceutical composition is for use in a method of treatment of a urinary tract infection.
- the pharmaceutical composition for use may be further characterized according to any one of the above (41) to (46).
- the prolonged-release pharmaceutical composition for oral administration has the features of the above (1) and (6).
- a prolonged-release pharmaceutical composition for oral administration which comprises: a) an immediate release component, comprising furazidin and one or more pharmaceutically acceptable excipients; and b) a modified-release component, comprising furazidin, a controlled-release agent, and one or more pharmaceutically acceptable excipients, wherein the pharmaceutical composition is a single dosage form comprising, in total, 150 to 250 mg of furazidin.
- the pharmaceutical composition for oral administration according to this aspect may be further characterized according to any one of the above (2) to (39).
- said pharmaceutical is for use in a method of treatment of a urinary tract infection.
- the pharmaceutical composition for use may be further characterized according to any one of the above (41) to (46).
- the prolonged-release pharmaceutical composition for oral administration has the features according to the above (1) and (37).
- a prolonged-release pharmaceutical composition for oral administration which comprises: a) an immediate release component, comprising furazidin and one or more pharmaceutically acceptable excipients; and b) a modified-release component, comprising furazidin, a controlled-release agent, and one or more pharmaceutically acceptable excipients, wherein the pharmaceutical composition is a single dosage form and configured to provide, after oral administration, a maximum plasma concentration of furazidin (Cmax) of 353.1 ⁇ 122.5 ng/mL after tmax of 2.5 ⁇ 0.5 hours after administration, and an area under the plasma concentration-time curve from time zero to 24 hours (AUC0-24) of 1404.1 ⁇ 392.8 ng h/mL, as determined by human PK studies.
- Cmax maximum plasma concentration of furazidin
- AUC0-24 area under the plasma concentration-time curve from time zero to 24 hours
- the pharmaceutical composition for oral administration according to this aspect may be further characterized according to any one of the above (2) to (36), (38) and (39).
- said pharmaceutical is for use in a method of treatment of a urinary tract infection.
- the pharmaceutical composition for use may be further characterized according to any one of the above (41) to (44) and (46).
- Prolonged-release pharmaceutical composition according to the present invention provides patients with an effective, safe and convenient therapy of UTI. Due to the prolonged release, the administration frequency of a single dosage form, in particular a tablet, of the pharmaceutical composition can be reduced to two times a day (BID), for example, for 5 to 8 days such as 7 days.
- BID two times a day
- the pharmaceutical composition can be conveniently taken 11 to 13 hours, preferably 12 hours, apart and in combination with a meal, that is, shortly before, together with or shortly after a meal (in particular, breakfast and dinner).
- “shortly” means within 30 minutes.
- the meals can be consumed at regular times (for example, 7 a.m. and 7 p.m.), without significantly adjusting the eating times to the dosage regimen.
- the prolonged release form of furazidin of the present invention provides more appropriate pharmacokinetic characteristics and, thus, improved efficacy compared to the immediate release tablets.
- the prolonged release form ensures maintaining a therapeutic level of the active substance over the time and, thus, enables twice a day (BID) administration. This is beneficial from both the clinical and the patient’s perspective, since there is no need for continuous control of administration of subsequent drug doses. Constant therapeutic blood and urine concentrations of the furazidin are maintained during the treatment and, by consequence, increased treatment effectiveness, which may lead to decreased recurrence or complication rate, is observed.
- the prolonged release dosage form prevents a rapid release of large quantities of furazidin and, thus, helps to minimise adverse effects such as the “first pass effect”.
- the pharmaceutical composition of the present invention also increases the patients’ quality of life.
- the present invention provides a prolonged-release pharmaceutical composition of furazidin, which provides better efficacy and safety profile than conventional immediate release furazidin tablets.
- PK pharmacokinetics
- a prolonged-release pharmaceutical composition for oral administration comprising: a) an immediate release component, comprising furazidin and one or more pharmaceutically acceptable excipients; and b) a modified-release component, comprising furazidin, a controlled-release agent, and one or more pharmaceutically acceptable excipients.
- An immediate release (IR) component releases furazidin with no special rate controlling features
- the modified-release (MR) component releases furazidin with a delay after its administration due to the controlled-release agent.
- the understanding of the terms correspond to common pharmaceutical handbook definitions.
- the immediate release component shows a release of the active substance, which is not deliberately modified by a special formulation and/or manufacturing method.
- the immediate-release (IR) component ensures that furazidin is available to the body without relevant impact of the dosage form.
- the IR component achieves in vitro dissolution of at least 80 wt.% of the furazidin within 45 minutes, based on the total furazidin content of the IR component.
- the modified-release component releases the active ingredient at a controlled rate, in particular, a constant rate.
- the release rate is independent from the pH, the ionic content, and other contents within the entire segment of the gastrointestinal tract, in particular the stomach and the small intestine.
- the modified-release component has an in vitro dissolution rate of 5 to 15 wt.% of furazidin within 2 h, based on the total furazidin content of the MR component.
- the 2-h time point of the dissolution profile has been chosen as representative for the correlation and referent for the prediction of the required full dissolution profile (up to release of the total amount of the API).
- CTAB hexadecyltrimethylammonium bromide
- the combination of IR component and MR component according to the present invention provides a prolonged-release pharmaceutical composition.
- the prolonged-release dosage form shows a sustained release of furazidin compared to that of prior art immediate release dosage forms administered by the same route.
- the prolonged-release pharmaceutical composition achieves in vitro dissolution rates of furazidin of 10 to 40 wt.%, preferably 10 to 30 %, within 1 h, 40 to 65 wt.% within 6 h and above 80 wt.% within 14 h, based on the total furazidin content of a single dosage form of the pharmaceutical composition.
- CTAB hexadecyltrimethylammonium bromide
- the prolonged-release pharmaceutical composition according to the invention may be understood as a biphasic release dosage form, in which the first phase of drug release is determined by a fast release dose fraction (immediate release component) providing a therapeutic drug level shortly after administration.
- the second extended release phase provides the dose fraction required to maintain an effective therapeutic level for a prolonged period.
- the pharmacokinetics of the pharmaceutical composition of the present invention thus differ fundamentally from the pharmacokinetics of prior art furazidin compositions for the treatment of UTI.
- the dosage frequency can be reduced to 2 times daily (BID), whereas prior art furazidin dosage forms require regular administration 3 or 4 times a day.
- the pharmaceutical composition can be conveniently administered in combination with a meal (that is, shortly before, together with or shortly after the meal), for example breakfast and dinner, without significantly adjusting the times when the meal is taken or which food is consumed.
- Furazidin compositions of the prior art require adjusting the eating times to the dosage regimen (e.g. 8 hours apart) and the intake of protein-rich food to improve the furazidin availability.
- the pharmaceutical composition of the present invention enhances the patients’ compliance as the pharmaceutical composition needs to be administered less often and the therapy is more convenient.
- furazidin is released in a controlled, in particular, constant manner, therapeutic plasma and urine concentrations of furazidin can be achieved more easily, which improves the therapeutic effect.
- the furazidin concentration can be maintained above the MIC values. Since only a part of the furazidin is released immediately from the pharmaceutical composition and then small doses are released from the modified-release component, the release of large furazidin quantities is avoided. The release of small quantities of furazidin minimizes adverse effects, such as the “first pass effect”.
- the pharmaceutical composition of the present invention enables an effective, safe and convenient therapy of UTI. Compliance and efficacy are improved, and sideeffects are reduced in comparison to furazidin compositions of the prior art.
- furazidin may be contained as the free base or as a pharmaceutically acceptable salt thereof.
- pharmaceutically acceptable salts are the sodium or the potassium salts of furazidin. Since the salts have a higher solubility, it is preferred that the MR component contains furazidin as the free base. More preferably, the pharmaceutical composition contains furazidin as the free base and no salts of furazidin.
- the pharmaceutical composition is a single dosage form in the form of a tablet.
- the immediate release component a) forms a first layer
- the modified-release component b) forms a second layer
- the first layer at least partially covers the surface of the second layer.
- the second layer may be completely surrounded by the first.
- the tablet is a bilayer tablet, which means that the first layer is arranged on one side (i.e. one of the two faces) of the second layer and, typically, covers this side completely. Such a tablet can be produced economically.
- the tablet may be uncoated or coated.
- the coating may, for example, be a film-coating.
- the tablet may have any suitable coating, e.g. functional coating. Such coatings can be found in the “Pharmaceutical Manufacturing Handbook" edited by Shayne Cox Gad, published by John Wiley & Sons, Inc., Hoboken, New Jersey, March 2008. Preferably, the tablet is uncoated.
- the IR component a) and the MR component b) may be compressed together, for example, by using a bilayer-tableting machine.
- the IR component and the MR component may also be granulated and then be compressed to a tablet, for example, by using a bilayer-tableting machine.
- the immediate release component a) is contained as granulates
- the modified-release component b) is contained as granulates, in the pharmaceutical composition, in particular, when the pharmaceutical composition is a bilayer tablet as the single dosage form.
- the granulates may be obtained by common dry or wet granulation techniques, preferably by wet granulation.
- the immediate release component a) and/or the modified-release component b) may also contain an extragranular fraction, for example, comprising one or more of a lubricant, a filler, an absorbent and a glidant.
- an extragranular fraction for example, comprising one or more of a lubricant, a filler, an absorbent and a glidant. The components of an extragranular fraction are added after formation of the granulates.
- the pharmaceutical composition is a single dosage form, in particular a bilayer tablet as described above, and comprises, in total, 150 to 250 mg of furazidin, preferably 180 to 220 mg of furazidin, and more preferably 200 mg of furazidin.
- a single dosage form has a higher furazidin content than a furazidin composition according to the prior art (100 mg or 50 mg).
- the immediate release component a) may contain 35 to 55 mg of furazidin
- the modified-release component b) may contain 145 to 165 mg of furazidin.
- the immediate release component a) contains 45 to 55 mg of furazidin, and the modified-release component b) contains 145 to 155 mg of furazidin. More preferably, the immediate release component a) contains 50 mg of furazidin, and the modified-release component b) comprises 150 mg of furazidin.
- the pharmaceutical composition according to this embodiment is particularly suitable for a dosage regimen, where a single dosage form is administered two times daily, preferably, 11 to 13 hours, more preferably 12 hours apart. It allows for particularly constant, therapeutic plasma and blood concentrations of furazidin, which improves the efficacy of the treatment of UCI and reduces adverse side-effects.
- the immediate release component a) has, in particular, a furazidin content of 32 to 50 wt.%, preferably 41 to 50 wt.%, more preferably 45 to 46 wt.%, such as 45.45 wt.%, based on the total weight of the immediate release component a).
- the modified release component b) has, in particular, a furazidin content of 40 to 60 wt.%, preferably 52 to 56 wt.%, more preferably 54 to 55 wt.%, such as 53.57 wt.%, based on the total weight of the modified-release component b).
- the modified-release component b) contains a controlled-release agent in order to modify and sustain the release of furazidin from the MR component. Due to the controlled-release agent, the MR component has the above in vitro release values.
- the immediate release component a) has no modified or prolonged release of furazidin as noted above.
- the controlled-release agent may be used in an amount of 4 to 35 wt.%, preferably 9 to 30 wt.%, more preferably 15 to 25 wt.%, based on the total mass of the composition.
- the modified-release component b) may comprise 10 to 40 wt.% of the controlled-release agent, preferably 10 to 35 wt.% and more preferably 20 to 30 wt.% of the controlled-release agent, based on the total weight of the modified-release component b).
- the controlled-release agent is contained in a matrix of the modified-release component b).
- the matrix of the modified-release component b) may be formed by the controlled-release agent or the controlled-release agent and a binder.
- the controlled-release agent is at least one pH-independent polymer.
- the matrix of the MR component is preferably formed by the pH-independent polymer or the pH- independent polymer and a binder (herein also denoted as “matrix of the pH-independent polymer”).
- furazidin is preferably dispersed or suspended in the matrix, such that the release is modified and prolonged.
- pH-independent polymer means that the polymer matrix exhibits pH- independent drug permeability and pH-independent swelling and, thus, enables modified release of the active ingredient by pH-independent swelling and erosion.
- pH-independent polymer means that the polymer matrix exhibits pH- independent drug permeability and pH-independent swelling and, thus, enables modified release of the active ingredient by pH-independent swelling and erosion.
- release of furazidin from such a polymer matrix is independent from the pH environment and the modified release according to the above in vitro dissolution values is fulfilled irrespective of the pH.
- pH-independenf means independent from the pH value in the gastrointestinal tract, which is usually between 1.5 and 8.5 (stomach and small intestine).
- a thickness ratio of the thickness of the matrix of the pH-independent polymer in a swollen state to the thickness of the dry matrix of the pH-independent polymer before swelling is in the range of 1.1 to 1.8, preferably 1.3 to 1.6, at each pH of 1.2, 4.5, 6.8 and 7.4, wherein the swollen state is obtained by immersing the dry modified release component b) in 30 to 35 mL of a solution contained in a beaker for 2 h, the beaker being placed in a wiggled, heated bath at 37°C, the solution being a phosphate buffer of pH 4.5, 6.8 or 7.4 or aqueous HC1 of pH 1.2.
- This allows for pH-independent drug permeability and pH-independent drug release from the MR component.
- the modified-release component has, in particular, an in vitro dissolution rate of 5 to 15 wt.% of furazidin within 2 h, based on the total furazidin content of the MR component.
- CTAB hexadecyltrimethylammonium bromide
- the pH-independent polymer provides a MR component having an in vitro dissolution rate at each pH of 1.2, 4.5 and 7.4, which is within a range of ⁇ 10% of the respective in vitro dissolution rate at a pH of 6.8.
- the drug release from the MR component is thus pH-independent.
- the pH-independent polymer is at least one selected from the group consisting of hydroxypropylmethylcellulose (HPMC), hydroxyethylcellulose (HEC), hydroxypropylcellulose, methylcellulose (MC), xanthan gum, sodium carboxymethylcellulose, non-ionic poly(ethylene oxide), copovidone (vinylpyrrolidone-vinyl acetate copolymer), and any combination thereof. More preferably, the pH-independent polymer has a weight average molecular weight (Mw) of 50,000 to 7,000,000, preferably 350,000 to 800,000.
- Mw weight average molecular weight
- HPMC hydroxypropylmethylcellulose
- CMC carboxymethylcellulose
- HEC hydroxy ethylcellulose
- MC methylcellulose
- copovidone have a weight average molecular weight of 50,000 to 100,000, preferably 45,000 to 70,000.
- the weight average molecular weights are measured by GPC/SEC according to EU Pharmacopoeia 5.0 method 2.2.30.
- Kollidon VA 64 and/or Plasdone S 630 or a combination of hydroxypropylmethylcellulose K15M and copovidone (e.g. Kollidon VA 64 and/or Plasdone S 630).
- Combinations of two pH- independent polymers are preferred for more adequately sustaining and controlling the furazidin release.
- pH-independent polymers can also serve as binders.
- such a compound can be used as both controlled-release agent and binder in the same pharmaceutical composition.
- the immediate release component a) and the modified-release component b) each comprise at least one excipient.
- the immediate release component a) may comprise at least one of a filler, a disintegrant, a binder, a lubricant, a glidant and any combination thereof.
- the immediate release component a) comprises a filler, a disintegrant, a glidant, a lubricant, and, optionally, a binder.
- the immediate release component a) preferably consists of furazidin and a filler, a disintegrant, a glidant, a lubricant, and, optionally, a binder.
- a binder is also present in the immediate-release component a).
- the modified-release component b) may comprise, as the at least one excipient, at least one of a filler, a disintegrant, a binder, a lubricant, a glidant and any combination thereof, preferably the modified-release component b) comprises a filler, a disintegrant, a binder, a lubricant, and, optionally, a glidant.
- the modified-release component b) preferably consists of furazidin, a controlled-release agent, a filler, a disintegrant, a binder, a lubricant, and, optionally, a glidant. More preferably, the MR component does not contain a glidant.
- the immediate release component a) and/or, preferably and, the prolonged-release component b) comprise a filler.
- a filler means at least one filler.
- the filler may be at least one filler independently selected from the group consisting of anhydrous or monohydrate lactose, sucrose, microcrystalline cellulose, starch such as maize starch, pregelatinized starch, microcrystalline cellulose coated with colloidal silica, mannitol and any combination thereof.
- the filler is at least one independently selected from the group consisting of anhydrous or monohydrate lactose, mannitol, microcrystalline cellulose, maize starch, saccharose and any combination thereof.
- the filler is at least one selected from the group consisting of lactose monohydrate, microcrystalline cellulose, or a combination thereof.
- the immediate release component a) may contain the filler in an amount of 10 to 50 wt.%, preferably 10 to 30 wt.%, based on the weight of the immediate release component a).
- the modified-release component b) contains the filler in an amount of 10 to 45 wt.%, preferably 10 to 30 wt.%, based on the weight of the modified-release component b).
- the immediate release component a) and/or the modified-release component b) comprise a binder.
- the immediate release component a) and the modified-release component b) comprise a binder, the binder being contained in addition to the controlled-release agent.
- a binder means at least one binder.
- the binder may, for example, be at least one binder independently selected from the group consisting of hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, carboxymethylcellulose, hydroxycellulose, hydroxyethylcellulose, polyvinyl alcohol, polyvinylpyrrolidone, copovidone, pregelatinized starch, gelatine and any combination thereof.
- the binder is at least one independently selected from the group consisting of hydroxypropyl cellulose, polyvinylpyrrolidone and any combination thereof. More preferably the binder is polyvinylpyrrolidone.
- the binder may be used in an amount equal to 0.4 to 5 wt.%, preferably 0.8 to 3 wt.%, more preferably 0.8 wt.%, based on the total mass of the composition.
- the immediate release component a) may contain the binder in an amount of 0.4 to 5 wt.%, preferably 0.4 to 3 wt.%, more preferably 0.5 wt.%, based on the weight of the immediate release component a).
- the modified-release component b) may contain the binder in an amount of 0.4 to 5 wt.%, preferably 0.4 to 3 wt.%, more preferably 0.9 wt.%, based on the weight of the modified-release component b).
- a binder is not required if the respective component is produced by dry granulation or direct compacting. It is however preferred to use wet granulation in the preparation of the components, where a binder is commonly used as described in more detail below.
- the immediate release component a) and/or, preferably and, the modified-release component b) comprise a disintegrant.
- a disintegrant means at least one disintegrant.
- the disintegrant may, for example, be at least one disintegrant independently selected from the group consisting of carboxymethylcellulose sodium salt, sodium croscarmellose, microcrystalline cellulose, crospovidone, sodium starch glycolate, maize starch, and any combination thereof.
- the disintegrant is at least one independently selected from the group consisting of sodium starch glycolate, sodium croscarmellose, maize starch and any combination thereof. More preferably, the disintegrant is sodium croscarmellose or sodium starch glycolate.
- the disintegrant may be used in an amount of 0.3 to 5 wt.%, preferably 1 to 4.5 wt.%, more preferably 3.6 wt.%, based on the total mass of the composition.
- the immediate release component a) may contain the disintegrant in an amount of 0.5 to 6 wt.%, preferably 2 to 6 wt.%, more preferably 5 wt.%, based on the weight of the immediate release component a).
- the modified-release component b) may contain the disintegrant in an amount of 0.3 to 5 wt.%, preferably 2 to 5 wt.%, more preferably 3 wt.%, based on the weight of the modified-release component b).
- the immediate release component a) and/or, preferably and, the modified-release component b) comprise a lubricant.
- a lubricant means at least one lubricant.
- the lubricant may, for example, be at least one lubricant independently selected from the group consisting of stearic acid, magnesium stearate, calcium stearate, sodium stearyl fumarate, glycerol tristearate, palm oil derivatives such as palmitic acid or hydrogenated palm oil, especially Softisan 154, hydrogenated vegetable oil, such as hydrogenated castor oil, and any combination thereof.
- the lubricant is at least one independently selected from magnesium stearate and stearic acid.
- the lubricant may be used in an amount of 1 to 10 wt.%, preferably 2 to 4 wt.%, more preferably 1.3 to 1.4 wt.% such as 1.35 wt.%, based on the total mass of the composition.
- the immediate release component a) may contain the lubricant in an amount of 2 to 4 wt.%, preferably 2.3 wt.%, based on the weight of the immediate release component a).
- the modified-release component b) may contain the lubricant in an amount of 0.5 to 2 wt.%, preferably 1 wt.%, based on the weight of the modified-release component b).
- the immediate release component a) and/or the modified-release component b) may comprise a glidant. It is preferred that the immediate release component a) but not the modified-release component b) comprises a glidant.
- a glidant means at least one glidant. Accordingly, the glidant may, for example, be at least one glidant independently selected from the group consisting of fumed silica (colloidal silicon dioxide), such as colloidal anhydrous silica, starch, talc and any combination thereof. Preferably, the glidant is colloidal anhydrous silica.
- the glidant may be used in an amount of 0.3 to 3 wt.%, preferably 0.4 to 2 wt.%, more preferably 0.46 wt.%, based on the total mass of the composition.
- the immediate release component a) may contain the glidant in an amount of 1.4 to 1.7 wt.%, preferably 1.6 wt.%, based on the weight of the immediate release component a).
- the modified-release component b) may contain the glidant in an amount of up to 1.3 wt.%, based on the weight of the modified-release component b).
- the immediate release component a) and/or the modified-release component b) comprise at least one absorbent as an excipient.
- An absorbent may, for example, be added to the granulate of the IR component or the MR component or the extragranular fraction in order to stabilize moisture level and, thus, to improve the quality of the physical properties of the granulate and facilitate subsequent compression of the granulate to form a tablet.
- the absorbent provides stabilisation of moisture level and pH of the granulate and of the final composition.
- the absorbent is preferably pH- neutral.
- the absorbent may, for example, be selected from magnesium aluminometasilicates.
- the absorbent is selected from one of the Neusilin grades, such as Neusilin US2® from Fuji Chemicals. In general, an absorbent is not required in the pharmaceutical composition.
- compositions of the present invention are obtained by combining preferred embodiments such as preferred contents and preferred components.
- the pharmaceutical composition is a single dosage form in the form of a bilayer tablet, in which the immediate release component a) forms a first layer, the modified-release component b) forms a second layer.
- the single dosage form of the pharmaceutical composition contains 150 to 250 mg of furazidin, preferably 180 to 220 mg of furazidin, and more preferably 200 mg of furazidin.
- the immediate release component a) comprises 35 to 55 mg, preferably 45 to 55 mg, more preferably 50 mg, of furazidin
- the modified-release component b) comprises 145 to 165 mg, preferably 145 to 155 mg, more preferably 150 mg, of furazidin.
- the modified-release component b) comprises 10 to 40 wt.%, preferably 10 to 35 wt.%, more preferably 20 to 30 wt.%, of a pH-independent polymer as the controlled-release agent, the pH-independent polymer being at least one selected from the group consisting of hydroxypropylmethylcellulose (HPMC), hydroxyethylcellulose (HEC), hydroxypropylcellulose, methylcellulose (MC), xanthan gum, sodium carboxymethylcellulose, non-ionic poly(ethylene oxide), copovidone (vinylpyrrolidone-vinyl acetate copolymer), and any combination thereof.
- HPMC hydroxypropylmethylcellulose
- HEC hydroxyethylcellulose
- MC methylcellulose
- xanthan gum sodium carboxymethylcellulose
- copovidone vinylpyrrolidone-vinyl acetate copolymer
- the immediate release component a) comprises 10 to 50 wt.%, preferably 10 to 30 wt.%, of a filler, 0.5 to 6 wt.%, preferably 2 to 6 wt.%, of a disintegrant, 1.4 to 1.7 wt.%, preferably 1.6 wt.%, of a glidant, 2 to
- the immediate release component a) may comprise 0.4 to 5 wt.%, preferably 0.4 to 3 wt.%, more preferably 0.5 wt.%, of a binder, based on the total weight of the immediate release component a).
- the filler, the disintegrant, the lubricant, the glidant and the binder are preferably selected from the above-mentioned compounds.
- the immediate release component a) may further contain 32 to 50 wt.%, preferably 41 to 50 wt.%, more preferably 45 to 46 wt.%, such as 45.45 wt.%, of furazidin and can consist of furazidin and the aforementioned excipients in the indicated amounts.
- the immediate release component a) contains or consist of 45.5 wt.% of furazidin, 29.5 wt.% of microcrystalline cellulose, 5.0 wt.% of sodium starch glycolate, 15.6 wt.% of maize starch, 1.6 wt.% of colloidal anhydrous silica, 2.3 wt.% of stearic acid and 0.5 wt.% of polyvinylpyrrolidone, based on the total weight of the immediate release component a).
- the modified-release component b) comprises 10 to 40 wt.%, preferably 10 to 35 wt.%, more preferably 20 to 30 wt.%, of the controlled-release agent, 10 to 45 wt.%, preferably 10 to 30 wt.%, of a filler, 0.3 to
- a disintegrant preferably 2 to 5 wt.%, more preferably 3 wt.%, of a disintegrant, 0.4 to 5 wt.%, preferably 0.9 wt.%, of a binder, 0.5 to 2 wt.%, preferably 1 wt.%, of a lubricant, and, optionally, up to 1.3 wt.% of a glidant, based on the total weight of the modified-release component b).
- it does not contain a glidant.
- the controlled-release agent, the filler, the disintegrant, the lubricant, the glidant and the binder are preferably selected from the above- mentioned compounds.
- the modified release component b) may further contain 40 to 60 wt.%, preferably 52 to 56 wt.%, more preferably 54 to 55 wt.%, such as 53.57 wt.%, of furazidin and can consist of furazidin and the consist of furazidin and the aforementioned excipients in the indicated amounts.
- the modified-release component b) contains or consists of 53.6 wt.% of furazidin, 13.6 wt.% of lactose monohydrate, 19.7 wt.% of hydroxypropylmethylcellulose K4M, 8.2 wt.% of hydroxy ethylcellulose, 3 wt.% of croscarmellose sodium, 1.0 wt.% of magnesium stearate and 0.9 wt.% of polyvinylpyrrolidone, based on the total weight of the immediate release component b).
- the IR component and MR component form a bilayer tablet and the MR component contains pH-independent polymer matrix allowing for the modified release of furazidin.
- the modified release of furazidin may be further characterized by the thickness of the pH-independent-polymer matrix after swelling, i.e. in the swollen state.
- Such a thickness of the swollen MR component is favourable for obtaining a controlled release of furazidin from the pH-independent polymer matrix and absorption in the upper part of the small intestine in order to obtain a desirable time/concentration profile of furazidin.
- Pharmacokinetics studies showed that furazidin in form of a prolonged release composition according to the present invention is mainly absorbed in the upper part of the small intestine.
- the dry modified-release component Before swelling, has a thickness in the range of 3.0 to 5.0 mm, preferably 3.5 - 4.0 mm.
- the thickness ratio of the thickness of the modified-release component b) in the swollen state to the thickness of the dry modified-release component b) before swelling is in the range of 1.1 to 1.8, preferably 1.3 to 1.6.
- the pharmaceutical composition of the present invention provides preferable pharmacokinetics as a controlled, preferably constant, release of furazidin is achieved.
- the pharmacokinetics obtained with the pharmaceutical composition of the present invention differ fundamentally from prior art furazidin compositions for the treatment of UTI, which basically show an immediate release of furazidin.
- the preferable pharmacokinetics allow for reducing the dosage frequency in the treatment of UTI, thus improving patients’ compliance and convenience and ensuring a better therapeutic efficacy.
- the pharmaceutical composition is a single dosage form, in particular in the form of a bilayer tablet, and configured to provide, after oral administration, a maximum plasma concentration of furazidin (Cmax) of 353.1 ⁇ 122.5 ng/mL after tmax of 2.5 ⁇ 0.5 hours after administration, and an area under the plasma concentrationtime curve from time zero to 24 hours (AUC0-24) of 1404.1 ⁇ 392.8 ng h/mL, as determined by human PK studies.
- Cmax maximum plasma concentration of furazidin
- AUC0-24 area under the plasma concentrationtime curve from time zero to 24 hours
- the pharmaceutical composition may be configured to provide, after oral administration of a single dosage form, in particular in the form of a bilayer tablet, of the pharmaceutical composition twice a day and 12 hours apart for 3 days, a maximum plasma concentration in steady state (C ma x,ss) of furazidin of 516.4 ⁇ 149.3 ng/mL and an area under the plasma concentration-time curve from time zero to 24 hours in steady state (AUCo-24,ss) of 3498.1 ⁇ 932.2 ng h/mL, as determined by human PK studies.
- C ma x,ss maximum plasma concentration in steady state
- AUCo-24,ss area under the plasma concentration-time curve from time zero to 24 hours in steady state
- CTAB hexadecyltrimethylammonium bromide
- the invention relates to the method of manufacturing the prolonged- release pharmaceutical composition.
- the method enables the production of the pharmaceutical composition using conventional tools and well-known pharmaceutical technologies, while significantly simplifying the manufacturing process, and reducing its costs comparing to manufacturing standards known in the art.
- the pharmaceutical composition in particular in the form of a bilayer tablet, can be prepared by a method comprising direct compression, dry granulation or wet granulation for making the immediate-release component and the modified- release component b).
- a method of manufacturing the prolonged-release pharmaceutical composition comprises (a) a step of preparing the immediate release component a); (b) a step of preparing the modified-release component b); (c) a step of combining the immediate release component a) and the modified-release component (b) to form a bilayer tablet, in which the immediate release component a) forms a first layer, the modified-release component (b) forms a second layer; and, optionally, (d) a step of forming a coating around the first and second layers obtained in step (c).
- no coating is formed, that is, step (d) is preferably not carried out.
- the IR component and MR component may be independently prepared using a dry or wet technology such as dry or wet granulation.
- a dry-granulated IR component or MR component can be obtained using direct dry granulation of a powder mixture comprising furazidin or a pharmaceutically acceptable salt thereof, suitable excipients as described above and, in case of the MR component, a controlled- release agent, as described above, in particular at least one pH-independent polymer. Other excipients can be also included, if needed. Suitable excipients, used in pharmacy, can be found in theticianHandbook of Pharmaceutical Excipients" edited by R. C. Rowe, P. J. Sheskey, and S. Owen, Pharmaceutical Press, edition VII.
- the dry granulation method used to obtain the IR component (step (a)) or the MR component (step (b)) can be selected from roller compaction and slugging. Methods known to the skilled person and are described, for example, in the “Pharmaceutical Manufacturing Handbook” edited by Shayne Cox Gad, published by John Wiley & Sons, Inc., Hoboken, New Jersey.
- a wet-granulated IR component or MR component can be obtained using a suitable granulation method known in the art using powder mixtures comprising furazidin or a pharmaceutically acceptable salt thereof, suitable excipients as described above and, in case of the MR component, a controlled-release agent, as described above, in particular at least one pH-independent polymer. Other excipients can be also included, if needed.
- the wet granulation method used to obtain the IR component (step (a)) or the MR component (step (b)) can be selected from low shear, high shear, and fluid bed granulation.
- the IR component and the MR component are obtained by wet granulation (steps (a) and (b)).
- Blending operations can be performed in a suitable blender, preferably in a container blender.
- the IR component a) and/or the MR component b) are prepared using dry granulation (steps (a) and (b)).
- the method preferably comprises the following steps: (I) blending furazidin or a pharmaceutically acceptable salt thereof with all excipients except lubricant and, in case of the MR component, with the at least one controlled-release agent to homogeneity; II) adding a part of the lubricant and subsequent blending; III) dry granulation by roller-compaction or slugging; IV) breakingdown the resulting slugs or sheets using a milling technique to produce granules; V) adding the remaining part of lubricant and subsequent blending.
- the primary powder blend particles are aggregated under high pressure using one of two main dry granulation processes: either roller-compaction or slugging.
- the intermediate products, slugs or sheets are broken down using a suitable milling technique to produce granular material, which can be additionally sieved to separate the desired size fraction.
- a furazidin powder blend is very advantageous for several reasons. It allows for the elimination of water, which may affect furazidin stability, and obtaining a granulate having grain sizes that are optimal for further processing (combination with the second component comprising furazidin and optional extragranular phase component without the effect of physical segregation). Additionally, a broad ratio (wt.%) of furazidin can be blended into the dry granulate intermediate, which is not possible in other dry pharmaceutical processes (e.g. direct compression).
- the IR component a) and/or the MR component b) are prepared using wet granulation (steps (a) and (b)).
- the method preferably comprises the following steps: I) mixing of furazidin or a pharmaceutically acceptable salt thereof with at least one filler, at least one disintegrant, optionally further excipients, and, in case of the MR component, at least one controlled-release agent in a high- shear granulator to homogeneity; II) granulating the mixture of step I) by addition of a binder solution in water or another processing agent, such as an alcohol, e.g.
- Furazidin may be also subjected to a process of wet granulation (e.g. low shear, high shear or in a fluidized bed), to improve its solubility.
- Wet granulation facilitates obtaining the desired in vitro and in vivo release profiles.
- the resulting wet granulate is dried and, for example, screened to obtain a proper distribution of the particles, allowing a durable combination with the other component and additional excipients.
- the IR component a) is prepared using dry granulation (step (a)), and the MR component b) is prepared using wet granulation (step (b)). It is also preferred to prepare the IR component (step (a) and the MR component (step (b)) by wet granulation.
- step (c) of the method the resulting components a) and b) are combined together, and depending on the desired final form, for example, compressed into separate layers in a tablet, optionally followed by forming a coating in step (d), resulting in a single unit dosage form.
- the prolonged-release pharmaceutical composition is prepared by using a bilayer tableting technology in step (c).
- the present invention provides a method of treating UTI using a pharmaceutical composition as described herein above.
- the present invention provides a pharmaceutical composition as described herein above for use in a method of treatment of a urinary tract infection.
- the urinary tract infection is preferably an acute or recurrent uncomplicated urinary tract infection, for example caused by Escherichia coH. such as recurrent uncomplicated urinary tract infection in women caused by Escherichia coli.
- the pharmaceutical composition is a single dosage form, such as a bilayer tablet, which is administered orally two times daily, preferably 11 to 13 hours apart, more preferably 12 hours apart.
- the pharmaceutical composition is administered for 5 to 8 days, preferably 7 days.
- This regimen has the advantage of better patients’ compliance and improved quality of life during therapy in comparison to the treatment of UCI using a prior art furazidin composition.
- the high dosages of furazidin require large dosage forms, with the necessity of taking 2 or 4 tablets, depending on the available presentation, at once 3 or 4 times daily for 7 up to 10 days.
- the pharmaceutical composition is administered in combination with a meal, as absorption of furazidin is improved.
- combination with a meal means that the pharmaceutical composition is taken shortly before, together with or after the meal.
- the pharmaceutical composition is a single dosage form, which is administered orally within an interval of from 30 min before a meal and 30 min after a meal.
- the pharmaceutical composition is administered between at a meal and 30 min after a meal, and more preferably, right after the meal, that is, within 5 min after a meal.
- a single dosage form of the pharmaceutical composition usually contains 150 to 250 mg of furazidin, preferably 180 to 220 mg of furazidin, and more preferably 200 mg of furazidin.
- the immediate release component a) comprises 35 to 55 mg, preferably 45 to 55 mg, more preferably 50 mg, of furazidin
- the modified-release component b) comprises 145 to 165 mg, preferably 145 to 155 mg, more preferably 150 mg, of furazidin.
- 200 mg of furazidin formulated as a fixed dose comprising 50 mg of furazidin in IR component and 150 mg of furazidin in MR component is administered, 2 times daily, for example, for 7 days.
- the prolonged-release furazidin composition provides continuous furazidin effective concentration levels during the whole period of treatment, especially during the night. This effect could not be achieved with the use of a prior art immediate release formulation, which provides effective concentrations only during a short period of time after administration. Consequently, continuous bacteriostatic concentration in serum and urine could not be provided, which is however crucial for effective therapy.
- the method of treatment according to the present invention thus provides favourable furazidin pharmacokinetics, which are not obtained by prior art furazidin compositions.
- oral administration of one single dosage form of the pharmaceutical composition provides a maximum plasma concentration of furazidin (Cmax) of 353.1 ⁇ 122.5 ng/mL after tmax of 2.5 ⁇ 0.5 hours after administration, and an area under the plasma concentration-time curve from time zero to 24 hours (AUC0-24) of 1404.1 ⁇ 392.8 ng h/mL, as determined by human PK studies described below.
- oral administration of a single dosage form of the pharmaceutical composition twice a day and 12 hours apart provides after 3 days a maximum plasma concentration in steady state (C ma x,ss) of furazidin of 516.4 ⁇ 149.3 ng/mL and an area under the plasma concentration-time curve from time zero to 24 hours in steady state (AUCo-24,ss) of 3498.1 ⁇ 932.2 ng h/mL, as determined by human PK studies as described below.
- Fig. 1 shows the pharmacokinetic profiles of means in plasma of the food effect study of Example 5.
- Fig. 2 shows the pharmacokinetic profiles of means in urine of the food effect study of Example 5.
- Fig. 3 shows the pharmacokinetic profile of means in plasma of the multiple-dose study of Example 6.
- Fig. 4 shows the pharmacokinetic profile of means in urine of the multiple-dose study of Example 6.
- IR components IR/1 to IR/4
- MR components MR/1 to MR/15
- Table 1 Compositions of exemplary IR components
- IR/1 and IR/2 are prepared as follows:
- step 7 Blending the granulate obtained in step 7 with the part of maize starch, colloidal anhydrous silica (i.e. filler, glidant) after sizing.
- colloidal anhydrous silica i.e. filler, glidant
- IR/3 and IR/4 are prepared as follows:
- step 2 Blending all the components from step 1 except of the lubricant.
- the MR components MR/1 to MR/15 are prepared as follows:
- furazidin lactose monohydrate, hypromellose K4M, hydroxyethylcellulose 250L, croscarmellose sodium or the corresponding compounds (i.e. furazidin, filler, control release agent and disintegrant) in a high shear granulator.
- the final blend granulates are compressed into bilayer-tablets with the aid of rotary press machine. During the compression process, the following requirements of the tablets should be satisfied (Table 3).
- a bilayer tablet having the composition of IR/l+MR/1 in total 200 mg furazidin was used. Dissolution testing was performed using the following conditions:
- the quantities of drug substance released from the tested tablets are determined by HPLC.
- the mean value calculated from 6 tablets are indicated in Table 4.
- Table 5-1 shows dissolution results of selected MR components at a pH of 6.8.
- the MR components were pressed to tablets and subjected to a dissolution test using the above conditions.
- the sampling times are indicated in Tables 5-1 to 5-4.
- the mean value calculated from 6 samples is indicated. le 5-1.
- Dissolution data for exemplary MR components, pH 6.8
- Example 3 the swelling properties of the MR component having a pH-independent polymer matrix and the dissolution of furazidin from the MR component were investigated.
- the samples were prepared as follows. The test time and conditions are adjusted as to achieve complete dissolution of the IR layer and mimic the swelling characteristics of the MR component after 2 h mean retention time of the tested tablet in the stomach a after meal.
- Sample preparation Tablets, having the composition indicated in Tables 6-1 to 6-4 below, were produced as described above in Example 1.
- the beaker is placed in wiggled, heated bath at a temperature of 37°C.
- the tablets are incubated for 2 hours.
- the swollen samples were tested using a common texture analyser. Before testing, the probe of the texture analyser was calibrated against the testing platform (i.e. a blank slide).
- the swollen MR component i.e. the MR component is the swollen state
- the values of interest for a sample were obtained by a macro included in the software of the TA.XTplus Texture Analyser.
- the macro quantifies the measured gel thickness.
- the average of 5 tablets was calculated.
- Table 6 indicating the thickness of the MR component before swelling, the thickness range of the individual results after swelling, the average thickness after swelling and the swelling ratio (thickness before swelling/thickness in the swollen state).
- the 2h time point has been chosen as representative for the correlation and referent for the prediction of the required full dissolution profile.
- the dissolution values at the representative 2h time point showed a release of furazidin on the level of about 20 to 30 wt.% (a range of 10 to 35 wt.% is acceptable for a prolonged-release composition) for the bilayer tablets composed of IR component and MR component and a release of furazidin on the level of about 7 wt.% (a range of 5 to 15 wt.% was considered acceptable) for the MR component MR/3 when tested alone. It was found that the results are consistent with the expected levels of released furazidin over time to provide appropriate PK values in vivo.
- the final composition was packed in blisters, SBC 180/aluminum foil, and stored at long term (25°C/60% RH), intermediate (30°C/65% RH) and accelerated (40°C/75% RH) conditions.
- the level of impurities and the content of active substance were determined by HPLC according to the method disclosed in Journal of Pharmaceutical and Biomedical Analysis, Vol. 129 (2016), 433-440. The results are presented in Tables 8, 9 and 10.
- the requirements for the parameters tested during the stability study were established according to guidelines CPMP/ICH/367/96 (ICH Q6A), and CPMP/ICH/2738/99 (ICH Q3B (R2)). Table 9.
- Example 5 Phase I Clinical Trial Pivotal food effect study FUR-PK-03-19 (755/19) Study title: Randomized, open-label, three-period, cross-over, food effect pharmacokinetic study comparing bioavailability of furazidin, prolonged-release tablets, 200 mg having a composition of IR/l+MR/1 according to Example 1 in healthy subjects in different fed conditions. Aim of the study: The main study objective was to evaluate the pharmacokinetic properties and to compare the bioavailability of the Test product in healthy volunteers under different fed conditions.
- the pharmacokinetic data for plasma and urine were statistically analysed in 29 subjects. After single oral administration of furazidin, prolonged-release formulation, 200 mg to the healthy volunteers, peak plasma concentrations were reached at 2 hours (median) following administration under recommended fed conditions (high-protein meal). Cmax and AUCO-24 reached 353.1 ⁇ 122.5 ng/mL and 1404.1 ⁇ 392.8 ng*h/mL, respectively. Plasma concentrations of furazidin showed a mean terminal half-life of 1.0 hour in healthy subjects. The mean urine concentrations of furazidin under recommended fed conditions achieved 9971.867 ⁇ 3145.830 pg for Aeo-t and 1933.965 ⁇ 841.315 pg/h for Rmax. Peak urine concentrations were reached at 5 hours.
- AUC Total exposure
- AUC(6-24) Largest difference in exposure after meals versus fasting state is observed after 6 hours (AUC(6-24)), which implies a difference in profile shape resulting from a much larger increase in exposure at later times post dosing.
- High-fat, high calorie meal increases the exposure from 6 to 24 hours about 5.6- fold.
- Coadministration of the modified-release formulation with a high-protein meal increases overall plasma and urine levels in the same way as it was observed for the immediate release product (Furaginum Adamed 50 mg tablets).
- Aeo-t amount of unchanged drug excreted into the urine calculated as area under the urinary excretion rate curve from time zero to the last measurable rate
- Aeo-t amount of unchanged drug excreted into the urine calculated as area under the urinary excretion rate curve from time zero to the last measurable rate
- Aeo-t amount of unchanged drug excreted into the urine calculated as area under the urinary excretion rate curve from time zero to the last measurable rate
- Bioavailability was found to be 1.9-fold higher after high-protein meal and 2.5-fold higher after high-calorie/high-fat meal than under fasting conditions, (i.e. bioavailability after high- protein meal is about 25% lower than after high-calorie/high-fat meal).
- Peak plasma concentration was found to be 1.4-fold higher after high-protein meal and 1.7- fold higher after high calorie/high-fat meal than under fasting conditions, (i.e. peak plasma concentration after high-protein meal is about 19% lower than after high-calorie/high-fat meal).
- excreted amount of unchanged drug was found 1.9-fold higher after high-protein meal and 2.5-fold higher after high-calorie/high-fat meal than under fasting conditions, (i.e. excreted amount of unchanged drug after high-protein meal is about 25% lower than after high- calorie/high-fat meal).
- Urine excretion rate was found 1.4-fold higher after high-protein meal and 1.6-fold higher after high-calorie/high-fat meal than under fasting conditions, (i.e. urine excretion rate after high-protein meal is about 13% lower than after high-calorie/high-fat meal).
- the 90% confidence intervals for fedl*/fast, fed2*/fast and fedl*/fed2* ratios of LSM, based on In-transformed data of AUC(o-t) and Cmax were not found within the equivalence limits of 80.00-125.00 %. Hence, a significant food effect was confirmed.
- Furazidin administered orally should be taken at or after meals as this increases its bioavailability irrespective of the formulation or mechanisms of the drug release (MR or IR). Differences in concentrations after high-protein meal and after high-fat, high-calorie meal are statistically significant.
- the main study objective was to evaluate the pharmacokinetic properties and to compare the bioavailability of furazidin after multiple-dose administration of the Test product versus the Comparator product in healthy male and female volunteers under fed (high-protein meal) conditions.
- Test product 6 doses administered orally with 240 mL of water under fed (high-protein meal) conditions. Oral administration of one tablet given two times a day (12 hours interval apart). Total dose per day was 400 mg of furazidin. Dosing for 3 consecutive days (on Day 1, Day 2 and Day 3 twice a day). Multiple oral dose of Comparator product (9 doses) administered orally with 240 mL of water under fed (high- protein meal) conditions.
- the washout period was at least 7 days between the last dose in Period 1 and the first dose in Period 2. Blood samples were collected throughout a 76-hour period after the first IMP administration to characterize products absorption and elimination. Urine samples were collected over 24 hours post first dose on Day 1-Day 2 and over 28 hours post the first dose on Day 3 -Day 4.
- PK metrics AUC0-24, Cmax and AURC0-24
- PK metrics AUCo-24,ss (to reflect safety) and AURCo-24,Day3 (to reflect efficacy).
- Concentration-time profiles of Cthrough concentrations were provided to assess reaching of steady-state. High Cthrough variability was observed as usual for very low plasma concentration levels at time points beyond 5 times the plasma elimination half-life. This is not unexpected as the elimination half-life is approximately 1 hr and so, by the 12-hour interval, more than 95% of the absorbed dose is eliminated. In fact, the majority of subjects showed Cthrough levels below the limit of quantitation. Hence, a steady state based on similar Cthrough levels cannot be established as the pharmacokinetics of the product at the 12-hour dosage interval were essentially repeat single doses.
- the AUCo-24h, Cmax and AURCo-24h for Day 1 and AUCo -24h,ss and AURCo -24h,Day3 for Day 3 for furazidin were used to assess equivalence between both tested formulations.
- the results confirm that the 90% confidence intervals for Test to Comparator ratios of the geometric least squares means for above mentioned PK parameters were not within the bioequivalence acceptance range of 80.00% to 125.00%.
- tmax ss The time of maximum plasma drug concentration (h)
- Furazidin is mainly absorbed in the upper part of the small intestine. Bioavailability was found 1.9-fold higher after high-protein meal than under fasting conditions.
- the peak serum concentration 353.1 ⁇ 122.5 ng/mL (Cmax) was reached within approx. 2.5 hour (tmax)
- AUCo-24 reached 1404.1 ⁇ 392.8 ng*h/mL.
- the maximum serum concentration 256.7 ⁇ 87.3 ng/mL (Cmax) was reached within 2 hours (tmax).
- furazidin prolonged-release tablet 200 mg to the healthy volunteers for 3 days (twice a day, 12 hours apart), peak plasma concentrations were reached at about 51 hours following administration under fed conditions (high-protein meal).
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Communicable Diseases (AREA)
Abstract
The present invention relates to a prolonged-release pharmaceutical composition of furazidin for oral administration, which can be used for treating urinary tract infections (UTI). The prolonged-release pharmaceutical composition for oral administration comprises: a) an immediate release component, comprising furazidin and one or more pharmaceutically acceptable excipients; and b) a modified-release component, comprising furazidin, a controlled-release agent, and one or more pharmaceutically acceptable excipients.
Description
Prolonged-release furazidin composition
Description
Field of the present invention
The present invention relates to a prolonged-release pharmaceutical composition of furazidin for oral administration, which can be used for treating urinary tract infections (UTI).
Technological background
Urinary tract infections (UTI) are the most common condition requiring medical consultation and care in outpatients. UTIs account for approx. 10-20% of all community- acquired infections and for approx. 40-50% of nosocomial infections. Approx. 80% of all UTIs occur in women. According to epidemiological studies, bacteriuria occurs at least once in a lifetime of approx. 10% of female population and in 1-2% of male population, with asymptomatic UTIs in women probably occurring twice as frequently.
An uncomplicated urinary tract infection (uUTI) is a clinical syndrome characterized by pyuria and a documented microbial pathogen on urine culture, accompanied by local signs and symptoms such as urinary frequency, urinary urgency, dysuria, and suprapubic pain. Uncomplicated UTIs (uUTI), often also referred to as acute cystitis, occur in females with normal anatomy of the urinary tract and are not accompanied by systemic signs or symptoms, such as fever higher than 38 degrees Celsius or costovertebral angle pain. Urinary tract infections in males are characterized as complicated UTI (cUTI) because these infections occur in association with urologic abnormalities such as instrumentation or bladder outlet obstruction (e.g., benign prostatic hypertrophy).
A UTI is classified as uncomplicated if there are no relevant functional or anatomical anomalies in the urinary tract, no relevant renal functional impairment and no relevant concomitant disease that would promote the UTI, or the risk of developing serious complications. Examples of uncomplicated UTI include:
• Acute uncomplicated cystitis (AUC): A lower UTI (cystitis) is assumed when the acute symptoms refer only to the lower urinary tract, for example, urgency, pain on micturition (dysuria), frequency, and pain above the symphysis.
• Acute uncomplicated pyelonephritis: An upper UTI (pyelonephritis) ought to be assumed if, in the case of acute symptoms, flank pain, pain on palpation of the flank, and/or fever (>38°C) persist.
• Asymptomatic bacteriuria: Clinically symptomatic UTI is distinguished from asymptomatic bacteriuria. The term ‘asymptomatic UTI’ ought not to be used.
• Recurrent uncomplicated UTIs: A recurrent UTI is assumed if relapse rates of >2 symptomatic episodes occur within 6 months or >3 symptomatic episodes within 12 months.
UTIs are a significant clinical problem due to their serious sequelae, such as septic conditions, urolithiasis, renal failure, hypertension or occurrence of these complications during pregnancy. Community-acquired infections most often occur as a result of ascending invasion of native bacterial flora coming from the gastrointestinal tract. In typical cases, the first stage of infection is colonisation of the urinary meatus (in males; in females, the vestibule of the vagina), followed by urinary bladder invasion through the urethra. In women, because of the close proximity of the vagina, rectum and urinary meatus, shortness of the urethra as well as mechanical introduction of microorganisms into the urethra during sexual intercourse, the risk of infections is higher than in men.
Recurrent UTIs are defined as infections characterised by at least 3 episodes within one year or 2 episodes within 6 months. Infection recurrence is understood as a repeated UTI episode caused by the same micro-organism, i.e. by its endospores, within 3 weeks of the end of treatment. Such recurrences are often asymptomatic. Reinfections are repeated infections occurring after the urinary tract has been sterilised using antibacterial agents, but caused by a different bacterial strain, occurring up to 14 days after sterilisation of urine. In the population of young, healthy and sexually active women, 10% experience at least one UTI episode a year, and the risk of recurrent UTIs is approx. 0.5- 0.7/person/year.
Despite of the severe course and the recurrent nature of UTI, its treatment is still initiated empirically (without bacteriological assessment of urine). This means that, in a considerable proportion of patients treated with quinolines or trimethoprim/sulfamethoxazole (being a standard), this treatment might be unsuccessful due to increased antibiotic resistance to these products that has been witnessed in the recent years. In view of the epidemic of UTIs and the increasing drug resistance of bacterial strains, a need arises for an efficacious drug characterised by favourable safety, efficacy and patient acceptance profile.
Despite the growing microbial resistance, furazidin is efficient in the treatment of different forms of UTI. It is also safe, exhibiting less side effects, comparing to other antimicrobial agents and may be administered to children as well. The efficacy results from the high sensitivity of micro-organisms to furazidin. Moreover, the low resistance of uropathogens to furazidin is virtually unchanging in time, contrary to what is observed in the case of other
antibiotics or chemotherapeutic agents. Escherichia coli, the most frequent pathogen causing acute UTIs (70-95% of cases), is susceptible to furazidin at a constant level of approx. 90%, which has not changed for several decades, with simultaneous increase observed in drug resistance to quinolines or trimethoprim/sulfamethoxazole and fosfomycin. The unchanging and high susceptibility of microbial strains to furazidin makes it a very suitable candidate for the first-choice oral drug in empiric therapy of UTIs.
However, upon oral administration, furazidin has a very short half-life (below 1 hour). Blood drug concentrations of furazidin decrease very quickly after administration, reaching levels lower than the minimum concentration for exhibiting therapeutic effects. This creates a necessity of frequent administration of furazidin, which is according to the prior art administered in the form of immediate release (IR) tablets, containing 50 or 100 mg of furazidin. Due to the unfavourable pharmacokinetics, furazidin must be administered 3 to 4 times daily (each time 100 mg or 2 x 50 mg of furazidin) in order to maintain an effective concentration of furazidin in the plasma. Patient’s compliance is however difficult because patients are reluctant to take furazidin in constant intervals 3 or 4 times a day (up to 8 tablets), in particular, as furazidin should be taken with a meal. Thus, eating times need to be adjusted to the dosage regimen. Even under the assumption of patients’ complete adherence to the dosing schedule, it is very difficult to maintain therapeutic concentrations plasma and urine throughout the day.
Another problem associated with the conventional furazidin treatment is the “first pass effect”. Upon oral administration, furazidin is quickly absorbed in the gastrointestinal tract, reaching high blood concentrations. During this time, intensive liver metabolism occurs, causing exacerbation of adverse effects.
Summary of the invention
It is an object of the present invention to provide a pharmaceutical composition of furazidin that reduces or overcomes at least some of the above-mentioned problems.
The object is solved by the prolonged-release pharmaceutical composition and the pharmaceutical composition for use according to the appended claims.
In particular, the present invention relates to the following aspects:
(1) According to an aspect of the present invention, a prolonged-release pharmaceutical composition for oral administration is provided, the prolonged-release pharmaceutical composition comprising:
a) an immediate release component, comprising furazidin and one or more pharmaceutically acceptable excipients; and b) a modified-release component, comprising furazidin, a controlled-release agent, and one or more pharmaceutically acceptable excipients.
(2) The pharmaceutical composition according to (1), wherein furazidin is contained as the free base or as a pharmaceutically acceptable salt thereof, preferably as the free base.
(3) The pharmaceutical composition according to (1) or (2), wherein the pharmaceutical composition is a single dosage form in the form of a tablet, in which the immediate release component a) forms a first layer, the modified-release component b) forms a second layer, and the first layer at least partially covers the surface of the second layer. Preferably, the tablet is a bilayer tablet.
(4) The pharmaceutical composition according to (3), wherein the tablet is uncoated or coated. Preferably, the tablet is uncoated.
(5) The pharmaceutical composition according to any of (1) to (4), wherein the immediate release component a) is contained as granulates, and the modified-release component b) is contained as granulates. Optionally, the immediate release component a) and/or the modified- release component b) also contain an extragranular fraction, for example, comprising one or more of a lubricant, a filler, an absorbent and a glidant.
(6) The pharmaceutical composition according to any of (1) to (5), wherein the pharmaceutical composition is a single dosage form comprising, in total, 150 to 250 mg of furazidin, preferably 180 to 220 mg of furazidin, and more preferably 200 mg of furazidin.
(7) The pharmaceutical composition according to (6), wherein the immediate release component a) comprises 35 to 55 mg of furazidin, and the modified-release component b) comprises 145 to 165 mg of furazidin; and, preferably, the immediate release component a) comprises 45 to 55 mg of furazidin, and the modified-release component b) comprises 145 to 155 mg of furazidin; and, more preferably, the immediate release component a) comprises 50 mg of furazidin, and the modified-release component b) comprises 150 mg of furazidin.
(8) The pharmaceutical composition according to (6) or (7), wherein the immediate release component a) has a furazidin content of 32 to 50 wt.%, preferably 41 to 50 wt.%, more preferably 45 to 46 wt.%, such as 45.45 wt.%, based on the total weight of the immediate release component a); furthermore, the modified release component b) has a furazidin content of 40 to 60 wt.%, preferably 52 to 56 wt.%, more preferably 54 to 55 wt.%, such as 53.57 wt.%, based on the total weight of the modified-release component b).
(9) The pharmaceutical composition according to any one of (1) to (8), wherein the modified-release component b) comprises 10 to 40 wt.% of the controlled-release agent, preferably 10 to 35 wt.% and more preferably 20 to 30 wt.% of the controlled-release agent, based on the total weight of the modified-release component b).
(10) The pharmaceutical composition according to any one of (1) to (9), wherein, in a matrix of the modified-release component b), the controlled-release agent comprises at least one pH- independent polymer. Preferably, the matrix is formed by the pH-independent polymer, or by the pH-independent polymer and a binder. More preferably, a thickness ratio of the thickness of the matrix of the pH-independent polymer in a swollen state to the thickness of the dry matrix of the pH-independent polymer before swelling is in the range of 1.1 to 1.8, preferably 1.3 to 1.6, wherein the swollen state is obtained by immersing the dry modified release component b) in 30 to 35 mL of phosphate buffer of pH=4.5 contained in a beaker for 2 h, the beaker being placed in a wiggled, heated bath at 37°C. Still more preferably, a thickness ratio of the thickness of the matrix of the pH-independent polymer in a swollen state to the thickness of the dry matrix of the pH-independent polymer before swelling is in the range of 1.1 to 1.8, preferably 1.3 to 1.6, at each pH of 1.2, 4.5, 6.8 and 7.4, wherein the swollen state is obtained by immersing the dry modified release component b) in 30 to 35 mL of a solution contained in a beaker for 2 h, the beaker being placed in a wiggled, heated bath at 37°C, the solution being a phosphate buffer of pH 4.5, 6.8 or 7.4 or aqueous HC1 of pH 1.2.
(11) The pharmaceutical composition according to (9) or (10), wherein the pH-independent polymer is at least one selected from the group consisting of hydroxypropylmethylcellulose (HPMC), hydroxyethylcellulose (HEC), hydroxypropylcellulose, methylcellulose (MC), xanthan gum, sodium carboxymethylcellulose, non-ionic polyethylene oxide), copovidone (vinylpyrrolidone-vinyl acetate copolymer), and any combination thereof.
(12) The pharmaceutical composition according to (11), wherein the pH-independent polymer has a weight average molecular weight of 50,000 to 7,000,000, preferably 350,000 to 800,000. Preferred examples of hydroxypropylmethylcellulose (HPMC) have a weight average molecular weight (Mw) of 70,000 to 1,000,000, preferably 70,000 to 600,000, more preferably 70,000 to 170,000. Preferred examples of carboxymethylcellulose (CMC) have a weight average molecular weight of 200,000 to 500,000, preferably 350,000 to 450,000, more preferably 370,000 to 400,000. Preferred examples of hydroxyethylcellulose (HEC) have a weight average molecular weight of 50,000 to 200,000, preferably 80,000 to 150,000, more preferably 80,000 to 100,000. Preferred examples of methylcellulose (MC) have a weight average molecular weight of 12,000 to 280,000, preferably 10,000 to 220,000, more preferably
370,000 to 400,000. Preferred examples of copovidone have a weight average molecular weight of 50,000 to 100,000, preferably 45,000 to 70,000.
(13) The pharmaceutical composition according to (11) or (12), wherein the pH-independent polymer is
- a combination of hydroxypropylmethylcellulose K4M and hydroxy ethylcellulose,
- a combination of hydroxypropylmethylcellulose K4M and non-ionic polyethylene oxide),
- a combination of hydroxypropylmethylcellulose K4M and hydroxypropylmethylcellulose K100LV (Mw = 160,000 to 170,000),
- a combination of hydroxypropylmethylcellulose K4M and hydroxypropylcellulose,
- a combination of hydroxypropylmethylcellulose K15M and xanthan gum,
- a combination of hydroxypropylmethylcellulose K15M and sodium carboxymethylcellulose,
- a combination of hydroxypropylmethylcellulose K15M and methylcellulose A4MP or A15CP,
- methylcelluloses A4MP or A15CP,
- copovidone (vinylpyrrolidone-vinyl acetate copolymer) (e.g. Kollidon VA 64 and/or Plasdone S 630), or
- a combination of hydroxypropylmethylcellulose KI 5M and copovidone (e.g. Kollidon VA 64 and/or Plasdone S 630).
Preferably, the pH-independent polymer is a combination of hydroxypropylmethylcellulose K4M and hydroxy ethylcellulose.
(14) The pharmaceutical composition according to any one of (1) to (13), wherein the immediate release component a) comprises, as the at least one excipient, at least one of a filler, a disintegrant, a binder, a lubricant, a glidant and any combination thereof. Preferably the immediate release component a) comprises a filler, a disintegrant, a glidant, a lubricant, and, optionally, a binder. More preferably, the immediate release component a) contains a binder in addition to the filler, the disintegrant, the glidant and the lubricant.
(15) The pharmaceutical composition according to (1) to (14), wherein the modified-release component b) comprises, as the at least one excipient, at least one of a filler, a disintegrant, a binder, a lubricant, a glidant and any combination thereof. Preferably, the modified-release component b) comprises a filler, a disintegrant, a binder, a lubricant, and, optionally, a glidant. More preferably, the modified-release component b) contains no glidant.
(16) The pharmaceutical composition according to any one of (1) to (15), wherein the immediate release component a) and/or the prolonged-release component b) comprise a filler.
Preferably, the immediate release component a) and the prolonged-release component b) comprise a filler.
(17) The pharmaceutical composition according to (16), wherein the filler is at least one independently selected from the group consisting of anhydrous or monohydrate lactose, sucrose, microcrystalline cellulose, starch such as maize starch, pregelatinized starch, microcrystalline cellulose coated with colloidal silica, mannitol and any combination thereof, preferably the filler is at least one independently selected from the group consisting of anhydrous or monohydrate lactose, mannitol, microcrystalline cellulose, maize starch, saccharose and any combination thereof, and more preferably the filler is at least one selected from the group consisting of lactose monohydrate, microcrystalline cellulose, or a combination thereof.
(18) The pharmaceutical composition according to (16) or (17), wherein the immediate release component a) contains the filler in an amount of 10 to 50 wt.%, preferably 10 to 30 wt.%, based on the weight of the immediate release component a), and/or wherein the modified-release component b) contains the filler in an amount of 10 to 45 wt.%, preferably 10 to 30 wt.%, based on the weight of the modified-release component b).
(19) The pharmaceutical composition according to any one of (1) to (18), wherein the immediate release component a) and/or the modified-release component b) comprise a binder. Preferably, the immediate release component a) and the modified-release component b) comprise a binder.
(20) The pharmaceutical composition according to (19), wherein the binder is at least one independently selected from the group consisting of hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, carboxymethylcellulose, hydroxycellulose, hydroxyethylcellulose, polyvinyl alcohol, polyvinylpyrrolidone, copovidone, pregelatinized starch, gelatine and any combination thereof, preferably the binder is at least one independently selected from the group consisting of hydroxypropyl cellulose, polyvinylpyrrolidone and any combination thereof, and more preferably the binder is polyvinylpyrrolidone.
(21) The pharmaceutical composition according to (19) or (20), wherein the immediate release component a) contains the binder in an amount of 0.4 to 5 wt.%, preferably 0.5 wt.%, based on the weight of the immediate release component a), and/or wherein the modified- release component b) contains the binder in an amount of 0.4 to 5 wt.%, preferably 0.9 wt.%, based on the weight of the modified-release component b).
(22) The pharmaceutical composition according to any one of (1) to (21), wherein the immediate release component a) and/or the modified-release component b) comprise a
disintegrant. Preferably, the immediate release component a) and the modified-release component b) comprise a disintegrant.
(23) The pharmaceutical composition according to (22), wherein the disintegrant is at least one independently selected from the group consisting of carboxymethylcellulose sodium salt, sodium croscarmellose, microcrystalline cellulose, crospovidone, sodium starch glycolate, maize starch, and any combination thereof, preferably the disintegrant is at least one independently selected from the group consisting of sodium starch glycolate, sodium croscarmellose, maize starch and any combination thereof, more preferably the disintegrant is sodium croscarmellose or sodium starch glycolate.
(24) The pharmaceutical composition according to (22) or (23), wherein the immediate release component a) contains the disintegrant in an amount of 0.5 to 6 wt.%, preferably 2 to 6 wt.%, more preferably 5 wt.%, based on the weight of the immediate release component a), and/or wherein the modified-release component b) contains the disintegrant in an amount of 0.3 to 5 wt.%, preferably 2 to 5 wt.%, more preferably 3 wt.%, based on the weight of the modified-release component b).
(25) The pharmaceutical composition according to any one of (1) to (24), wherein the immediate release component a) and/or the modified-release component b) comprise a lubricant. Preferably, the immediate release component a) and the modified-release component b) comprise a lubricant.
(26) The pharmaceutical composition according to (25), wherein the lubricant is at least one independently selected from the group consisting of stearic acid, magnesium stearate, calcium stearate, sodium stearyl fumarate, glycerol tri stearate, palm oil derivatives such as palmitic acid or hydrogenated palm oil, hydrogenated vegetable oil, such as hydrogenated castor oil, and any combination thereof, preferably the lubricant is at least one independently selected from magnesium stearate and stearic acid.
(27) The pharmaceutical composition according to (24) or (25), wherein the immediate release component a) contains the lubricant in an amount of 2 to 4 wt.%, preferably 2.3 wt.%, based on the weight of the immediate release component a), and/or wherein the modified- release component b) contains the lubricant in an amount of 0.5 to 2 wt.%, preferably 1 wt.%, based on the weight of the modified-release component b).
(28) The pharmaceutical composition according to any one of (1) to (27), wherein the immediate release component a) and/or the modified-release component b) comprise a glidant. Preferably, the immediate release component a) but not the modified-release component b) comprises a glidant.
(29) The pharmaceutical composition according to (28), wherein the glidant is at least one independently selected from the group consisting of fumed silica (colloidal silicon dioxide), such as colloidal anhydrous silica, starch, talc and any combination thereof, preferably the glidant is colloidal anhydrous silica.
(30) The pharmaceutical composition according to (28) or (29), wherein the immediate release component a) contains the glidant in an amount of 1.4 to 1.7 wt.%, preferably 1.6 wt.%, based on the weight of the immediate release component a), and/or wherein the modified- release component b) contains the glidant in an amount of up to 1.3 wt.%, based on the weight of the modified-release component b), and preferably the modified-release component b) contains no glidant.
(31) The pharmaceutical composition according to any one of (1) to (30), wherein the immediate release component a) comprises 10 to 50 wt.%, preferably 10 to 30 wt.%, of a filler, 0.5 to 6 wt.%, preferably 2 to 6 wt.%, of a disintegrant, 1.4 to 1.7 wt.%, preferably 1.6 wt.%, of a glidant, 2 to 4 wt.%, preferably 2.3 wt.%, of a lubricant, based on the total weight of the immediate release component a).
(32) The pharmaceutical composition according to any one of (1) to (31), wherein the immediate release component a) comprises 0.4 to 5 wt.%, preferably 0.4 to 3 wt.%, more preferably 0.5 wt.%, of a binder, based on the total weight of the immediate release component a).
(33) The pharmaceutical composition according to any one of (1) to (32), wherein the modified-release component b) comprises 10 to 40 wt.%, preferably 10 to 35 wt.%, more preferably 20 to 30 wt.%, of the controlled-release agent, 10 to 45 wt.%, preferably 10 to 30 wt.%, of a filler, 0.3 to 5 wt.%, preferably 2 to 5 wt.%, more preferably 3 wt.%, of a disintegrant, 0.4 to 5 wt.%, preferably 0.9 wt.%, of a binder, 0.5 to 2 wt.%, preferably 1 wt.%, of a lubricant, and, optionally, up to 1.3 wt.% of a glidant and preferably no glidant, based on the total weight of the modified-release component b).
(34) The pharmaceutical composition according to any one of (1) to (33), wherein the immediate release component a) contains 45.5 wt.% of furazidin, 29.5 wt.% of microcrystalline cellulose, 5.0 wt.% of sodium starch glycolate, 15.6 wt.% of maize starch, 1.6 wt.% of colloidal anhydrous silica, 2.3 wt.% of stearic acid and 0.5 wt.% of polyvinylpyrrolidone, based on the total weight of the immediate release component a).
(35) The pharmaceutical composition according to any one of (1) to (34), wherein the modified-release component b) contains 53.6 wt.% of furazidin, 13.6 wt.% of lactose monohydrate, 19.7 wt.% of hydroxypropylmethylcellulose K4M, 8.2 wt.% of
hydroxy ethylcellulose, 3 wt.% of croscarmellose sodium, 1.0 wt.% of magnesium stearate and 0.9 wt.% of polyvinylpyrrolidone, based on the total weight of the immediate release component b).
(36) The pharmaceutical composition according to any one of (9) to (35), wherein, after immersing the modified-release component b) in 30 to 35 mL of phosphate buffer of pH=4.5 for 2 hours, the buffer being contained in a beaker, heated by a wiggled, heated bath at 37°C, the matrix of the modified-release component b) is in a swollen state and has a thickness in the range of 4.1 to 6.6 mm, preferably 4.9 to 5.5 mm.
(37) The pharmaceutical composition according to any one of (1) to (36), wherein the pharmaceutical composition is a single dosage form and configured to provide, after oral administration, a maximum plasma concentration of furazidin (Cmax) of 353.1±122.5 ng/mL after tmax of 2.5±0.5 hours after administration, and an area under the plasma concentrationtime curve from time zero to 24 hours (AUC0-24) of 1404.1±392.8 ng h/mL, as determined by human PK studies.
(38) The pharmaceutical composition according to any one of (1) to (37), wherein the pharmaceutical composition is configured to provide, after oral administration of a single dosage form of the pharmaceutical composition twice a day and 12 hours apart for 3 days, a maximum plasma concentration in steady state (Cmax,ss) of furazidin of 516.4±149.3 ng/mL and an area under the plasma concentration-time curve from time zero to 24 hours in steady state (AUCO-24,SS) of 3498.1±932.2 ng h/mL, as determined by human PK studies.
(39) The pharmaceutical composition according to any one of (1) to (38), wherein the pharmaceutical composition is a single dosage form and has an in vitro dissolution rate of furazidin of 10 to 40 wt.%, preferably 10 to 30 %, within 1 h, 40 to 65 wt.% within 6 h and above 80 wt.% within 14 h, based on the total furazidin content of the single dosage form, as determined by using European Pharmacopoeia edition 10 Apparatus Baskets “1” in 1000 mL volume of phosphate buffer solution of pH=6.8 with the addition of 2.5% CTAB (hexadecyltrimethylammonium bromide) at 37.0°C±0.5°C and 100 rpm.
(40) According to a further aspect, the present invention relates to a pharmaceutical composition as defined in any one of (1) to (39) for use in a method of treatment of a urinary tract infection.
(41) The pharmaceutical composition for use according to (40), wherein the urinary tract infection is an acute or recurrent uncomplicated urinary tract infection, such as infections in women caused by Escherichia coli.
(42) The pharmaceutical composition for use according to (40) or (41), wherein the pharmaceutical composition is a single dosage form, which is administered orally two times daily, preferably 11 to 13 hours apart, more preferably 12 hours apart.
(43) The pharmaceutical composition for use according to any one of (40) to (42), wherein the pharmaceutical composition is a single dosage form, which is administered orally within an interval of from 30 min before a meal and 30 min after a meal, preferably between at a meal and 30 min after a meal.
(44) The pharmaceutical composition for use according to any one of (40) to (43), wherein the pharmaceutical composition is administered for 5 to 8 days, preferably 7 days.
(45) The pharmaceutical composition for use according to any one of (40) to (44), wherein oral administration of one single dosage form of the pharmaceutical composition provides a maximum plasma concentration of furazidin (Cmax) of 353.1±122.5 ng/mL after tmax of 2.5±0.5 hours after administration, and an area under the plasma concentration-time curve from time zero to 24 hours (AUC0-24) of 1404.1±392.8 ng h/mL, as determined by human PK studies.
(46) The pharmaceutical composition for use according to any one of (40) to (45), wherein oral administration of a single dosage form of the pharmaceutical composition twice a day and 12 hours apart provides after 3 days a maximum plasma concentration in steady state (Cmax,ss) of furazidin of 516.4±149.3 ng/mL and an area under the plasma concentration-time curve from time zero to 24 hours in steady state (AUCo-24,ss) of 3498.1±932.2 ng h/mL, as determined by human PK studies.
According to a preferred aspect of the present invention, the prolonged-release pharmaceutical composition for oral administration has the features according to the above (1) and (3). Thus, a the prolonged-release pharmaceutical composition for oral administration is provided, which comprises: a) an immediate release component, comprising furazidin and one or more pharmaceutically acceptable excipients; and b) a modified-release component, comprising furazidin, a controlled-release agent, and one or more pharmaceutically acceptable excipients, wherein the pharmaceutical composition is a single dosage form in the form of a bilayer tablet, in which the immediate release component a) forms a first layer, the modified- release component b) forms a second layer. The pharmaceutical composition for oral administration according to this aspect may be further characterized according to any one of the above (2) and (4) to (39). According to a further aspect, the said pharmaceutical composition is for use in a method of treatment of a urinary tract infection. The pharmaceutical composition for use may be further characterized according to any one of the above (41) to (46).
According to a further preferred aspect of the present invention, the prolonged-release pharmaceutical composition for oral administration has the features of the above (1) and (6). Thus, a prolonged-release pharmaceutical composition for oral administration is provided, which comprises: a) an immediate release component, comprising furazidin and one or more pharmaceutically acceptable excipients; and b) a modified-release component, comprising furazidin, a controlled-release agent, and one or more pharmaceutically acceptable excipients, wherein the pharmaceutical composition is a single dosage form comprising, in total, 150 to 250 mg of furazidin. The pharmaceutical composition for oral administration according to this aspect may be further characterized according to any one of the above (2) to (39). According to a further aspect, said pharmaceutical is for use in a method of treatment of a urinary tract infection. The pharmaceutical composition for use may be further characterized according to any one of the above (41) to (46).
According to further preferred aspect of the present invention, the prolonged-release pharmaceutical composition for oral administration has the features according to the above (1) and (37). Thus, a prolonged-release pharmaceutical composition for oral administration is provided, which comprises: a) an immediate release component, comprising furazidin and one or more pharmaceutically acceptable excipients; and b) a modified-release component, comprising furazidin, a controlled-release agent, and one or more pharmaceutically acceptable excipients, wherein the pharmaceutical composition is a single dosage form and configured to provide, after oral administration, a maximum plasma concentration of furazidin (Cmax) of 353.1±122.5 ng/mL after tmax of 2.5±0.5 hours after administration, and an area under the plasma concentration-time curve from time zero to 24 hours (AUC0-24) of 1404.1±392.8 ng h/mL, as determined by human PK studies. The pharmaceutical composition for oral administration according to this aspect may be further characterized according to any one of the above (2) to (36), (38) and (39). According to a further aspect, said pharmaceutical is for use in a method of treatment of a urinary tract infection. The pharmaceutical composition for use may be further characterized according to any one of the above (41) to (44) and (46).
Prolonged-release pharmaceutical composition according to the present invention provides patients with an effective, safe and convenient therapy of UTI. Due to the prolonged release, the administration frequency of a single dosage form, in particular a tablet, of the pharmaceutical composition can be reduced to two times a day (BID), for example, for 5 to 8
days such as 7 days. The pharmaceutical composition can be conveniently taken 11 to 13 hours, preferably 12 hours, apart and in combination with a meal, that is, shortly before, together with or shortly after a meal (in particular, breakfast and dinner). Here “shortly” means within 30 minutes. The meals can be consumed at regular times (for example, 7 a.m. and 7 p.m.), without significantly adjusting the eating times to the dosage regimen.
Patients using such a therapy would find it easier to take the drug regularly as scheduled, leading to an increase of the compliance. Furthermore, the prolonged release form of furazidin of the present invention provides more appropriate pharmacokinetic characteristics and, thus, improved efficacy compared to the immediate release tablets. The prolonged release form ensures maintaining a therapeutic level of the active substance over the time and, thus, enables twice a day (BID) administration. This is beneficial from both the clinical and the patient’s perspective, since there is no need for continuous control of administration of subsequent drug doses. Constant therapeutic blood and urine concentrations of the furazidin are maintained during the treatment and, by consequence, increased treatment effectiveness, which may lead to decreased recurrence or complication rate, is observed. Additionally, the prolonged release dosage form prevents a rapid release of large quantities of furazidin and, thus, helps to minimise adverse effects such as the “first pass effect”.
By deteriorating circumstances of UTI patients, the pharmaceutical composition of the present invention also increases the patients’ quality of life. The present invention provides a prolonged-release pharmaceutical composition of furazidin, which provides better efficacy and safety profile than conventional immediate release furazidin tablets.
The efficacy and pharmacokinetics (PK) of the pharmaceutical composition according to the present invention have been confirmed in Phase I, pivotal, randomized, open-label, three- period, cross-over, food effect study under fasting and fed (high protein meal and high calorie/high fat meal) conditions and Phase I, pivotal, randomized, open-label, two-period, multiple dose, cross-over bioavailability study under fed conditions.
Detailed description
According to an aspect of the present invention, a prolonged-release pharmaceutical composition for oral administration is provided, the prolonged-release pharmaceutical composition comprising: a) an immediate release component, comprising furazidin and one or more pharmaceutically acceptable excipients; and b) a modified-release component, comprising furazidin, a controlled-release agent, and one or more pharmaceutically acceptable excipients.
An immediate release (IR) component releases furazidin with no special rate controlling features, whereas the modified-release (MR) component releases furazidin with a delay after its administration due to the controlled-release agent. The understanding of the terms correspond to common pharmaceutical handbook definitions. The immediate release component shows a release of the active substance, which is not deliberately modified by a special formulation and/or manufacturing method. The immediate-release (IR) component ensures that furazidin is available to the body without relevant impact of the dosage form. In particular, according to the present invention, the IR component achieves in vitro dissolution of at least 80 wt.% of the furazidin within 45 minutes, based on the total furazidin content of the IR component. The modified-release component releases the active ingredient at a controlled rate, in particular, a constant rate. Preferably, the release rate is independent from the pH, the ionic content, and other contents within the entire segment of the gastrointestinal tract, in particular the stomach and the small intestine. In particular, according to the present invention, the modified-release component has an in vitro dissolution rate of 5 to 15 wt.% of furazidin within 2 h, based on the total furazidin content of the MR component. The 2-h time point of the dissolution profile has been chosen as representative for the correlation and referent for the prediction of the required full dissolution profile (up to release of the total amount of the API). The aforementioned in vitro dissolution rates are determined by using European Pharmacopoeia edition 10 Apparatus Baskets “1” in 1000 mL volume of phosphate buffer solution of pH=6.8 with the addition of 2.5% CTAB (hexadecyltrimethylammonium bromide) at 37.0°C±0.5°C and 100 rpm.
The combination of IR component and MR component according to the present invention provides a prolonged-release pharmaceutical composition. The prolonged-release dosage form shows a sustained release of furazidin compared to that of prior art immediate release dosage forms administered by the same route. In particular, the prolonged-release pharmaceutical composition achieves in vitro dissolution rates of furazidin of 10 to 40 wt.%, preferably 10 to 30 %, within 1 h, 40 to 65 wt.% within 6 h and above 80 wt.% within 14 h, based on the total furazidin content of a single dosage form of the pharmaceutical composition. The in vitro dissolution rates are determined by using European Pharmacopoeia edition 10 Apparatus Baskets “1” in 1000 mL volume of phosphate buffer solution of pH=6.8 with the addition of 2.5% CTAB (hexadecyltrimethylammonium bromide) at 37.0°C±0.5°C and 100 rpm.
The inventors have found that a prolonged, in particular more constant, release of furazidin can be achieved by the combination of IR component and MR component, as the immediate release is combined with a modified, controlled release. In other words, a
component having a high release rate is combined with a component having a prolonged release rate as reflected by the in vitro dissolution rates of furazidin of the IR and MR components. More precisely, the prolonged-release pharmaceutical composition according to the invention may be understood as a biphasic release dosage form, in which the first phase of drug release is determined by a fast release dose fraction (immediate release component) providing a therapeutic drug level shortly after administration. The second extended release phase provides the dose fraction required to maintain an effective therapeutic level for a prolonged period. The pharmacokinetics of the pharmaceutical composition of the present invention thus differ fundamentally from the pharmacokinetics of prior art furazidin compositions for the treatment of UTI.
The inventors have surprisingly found that, due to the combination of IR component and MR component, having different furazidin release properties, the dosage frequency can be reduced to 2 times daily (BID), whereas prior art furazidin dosage forms require regular administration 3 or 4 times a day. Moreover, the pharmaceutical composition can be conveniently administered in combination with a meal (that is, shortly before, together with or shortly after the meal), for example breakfast and dinner, without significantly adjusting the times when the meal is taken or which food is consumed. Furazidin compositions of the prior art require adjusting the eating times to the dosage regimen (e.g. 8 hours apart) and the intake of protein-rich food to improve the furazidin availability. Thus, the pharmaceutical composition of the present invention enhances the patients’ compliance as the pharmaceutical composition needs to be administered less often and the therapy is more convenient.
Since furazidin is released in a controlled, in particular, constant manner, therapeutic plasma and urine concentrations of furazidin can be achieved more easily, which improves the therapeutic effect. In particular, the furazidin concentration can be maintained above the MIC values. Since only a part of the furazidin is released immediately from the pharmaceutical composition and then small doses are released from the modified-release component, the release of large furazidin quantities is avoided. The release of small quantities of furazidin minimizes adverse effects, such as the “first pass effect”.
In conclusion, the pharmaceutical composition of the present invention enables an effective, safe and convenient therapy of UTI. Compliance and efficacy are improved, and sideeffects are reduced in comparison to furazidin compositions of the prior art.
In the pharmaceutical composition, furazidin may be contained as the free base or as a pharmaceutically acceptable salt thereof. Examples of pharmaceutically acceptable salts are the
sodium or the potassium salts of furazidin. Since the salts have a higher solubility, it is preferred that the MR component contains furazidin as the free base. More preferably, the pharmaceutical composition contains furazidin as the free base and no salts of furazidin.
According to an embodiment, the pharmaceutical composition is a single dosage form in the form of a tablet. In the tablet, the immediate release component a) forms a first layer, the modified-release component b) forms a second layer, and the first layer at least partially covers the surface of the second layer. The second layer may be completely surrounded by the first. However, it is preferable that the tablet is a bilayer tablet, which means that the first layer is arranged on one side (i.e. one of the two faces) of the second layer and, typically, covers this side completely. Such a tablet can be produced economically.
The tablet may be uncoated or coated. The coating may, for example, be a film-coating. The tablet may have any suitable coating, e.g. functional coating. Such coatings can be found in the “Pharmaceutical Manufacturing Handbook" edited by Shayne Cox Gad, published by John Wiley & Sons, Inc., Hoboken, New Jersey, March 2008. Preferably, the tablet is uncoated.
In the pharmaceutical composition, the IR component a) and the MR component b) may be compressed together, for example, by using a bilayer-tableting machine. The IR component and the MR component may also be granulated and then be compressed to a tablet, for example, by using a bilayer-tableting machine. Preferably, the immediate release component a) is contained as granulates, and the modified-release component b) is contained as granulates, in the pharmaceutical composition, in particular, when the pharmaceutical composition is a bilayer tablet as the single dosage form. The granulates may be obtained by common dry or wet granulation techniques, preferably by wet granulation. In addition to granulates, the immediate release component a) and/or the modified-release component b) may also contain an extragranular fraction, for example, comprising one or more of a lubricant, a filler, an absorbent and a glidant. The components of an extragranular fraction are added after formation of the granulates.
According to an embodiment, the pharmaceutical composition is a single dosage form, in particular a bilayer tablet as described above, and comprises, in total, 150 to 250 mg of furazidin, preferably 180 to 220 mg of furazidin, and more preferably 200 mg of furazidin. Thus, a single dosage form has a higher furazidin content than a furazidin composition according to the prior art (100 mg or 50 mg). In the pharmaceutical composition, the immediate release component a) may contain 35 to 55 mg of furazidin, and the modified-release component b) may contain 145 to 165 mg of furazidin. Preferably, the immediate release component a) contains 45 to 55 mg of furazidin, and the modified-release component b)
contains 145 to 155 mg of furazidin. More preferably, the immediate release component a) contains 50 mg of furazidin, and the modified-release component b) comprises 150 mg of furazidin. The pharmaceutical composition according to this embodiment is particularly suitable for a dosage regimen, where a single dosage form is administered two times daily, preferably, 11 to 13 hours, more preferably 12 hours apart. It allows for particularly constant, therapeutic plasma and blood concentrations of furazidin, which improves the efficacy of the treatment of UCI and reduces adverse side-effects.
In the aforementioned embodiment, the immediate release component a) has, in particular, a furazidin content of 32 to 50 wt.%, preferably 41 to 50 wt.%, more preferably 45 to 46 wt.%, such as 45.45 wt.%, based on the total weight of the immediate release component a). Furthermore, the modified release component b) has, in particular, a furazidin content of 40 to 60 wt.%, preferably 52 to 56 wt.%, more preferably 54 to 55 wt.%, such as 53.57 wt.%, based on the total weight of the modified-release component b).
In the pharmaceutical composition, the modified-release component b) contains a controlled-release agent in order to modify and sustain the release of furazidin from the MR component. Due to the controlled-release agent, the MR component has the above in vitro release values. The immediate release component a) has no modified or prolonged release of furazidin as noted above. In the pharmaceutical composition, the controlled-release agent may be used in an amount of 4 to 35 wt.%, preferably 9 to 30 wt.%, more preferably 15 to 25 wt.%, based on the total mass of the composition. The modified-release component b) may comprise 10 to 40 wt.% of the controlled-release agent, preferably 10 to 35 wt.% and more preferably 20 to 30 wt.% of the controlled-release agent, based on the total weight of the modified-release component b).
According to a preferred embodiment, the controlled-release agent is contained in a matrix of the modified-release component b). The matrix of the modified-release component b) may be formed by the controlled-release agent or the controlled-release agent and a binder. Preferably, the controlled-release agent is at least one pH-independent polymer. Hence, the matrix of the MR component is preferably formed by the pH-independent polymer or the pH- independent polymer and a binder (herein also denoted as “matrix of the pH-independent polymer”). In the MR component, furazidin is preferably dispersed or suspended in the matrix, such that the release is modified and prolonged.
The term “pH-independent polymer” means that the polymer matrix exhibits pH- independent drug permeability and pH-independent swelling and, thus, enables modified release of the active ingredient by pH-independent swelling and erosion. Thus, the release of
furazidin from such a polymer matrix is independent from the pH environment and the modified release according to the above in vitro dissolution values is fulfilled irrespective of the pH. “pH-independenf ’ means independent from the pH value in the gastrointestinal tract, which is usually between 1.5 and 8.5 (stomach and small intestine). More preferably, a thickness ratio of the thickness of the matrix of the pH-independent polymer in a swollen state to the thickness of the dry matrix of the pH-independent polymer before swelling is in the range of 1.1 to 1.8, preferably 1.3 to 1.6, wherein the swollen state is obtained by immersing the dry modified-release component b) in 30 to 35 mL of phosphate buffer of pH=4.5 contained in a beaker for 2 h, the beaker being placed in a wiggled, heated bath at 37°C. Still more preferably, a thickness ratio of the thickness of the matrix of the pH-independent polymer in a swollen state to the thickness of the dry matrix of the pH-independent polymer before swelling is in the range of 1.1 to 1.8, preferably 1.3 to 1.6, at each pH of 1.2, 4.5, 6.8 and 7.4, wherein the swollen state is obtained by immersing the dry modified release component b) in 30 to 35 mL of a solution contained in a beaker for 2 h, the beaker being placed in a wiggled, heated bath at 37°C, the solution being a phosphate buffer of pH 4.5, 6.8 or 7.4 or aqueous HC1 of pH 1.2. This allows for pH-independent drug permeability and pH-independent drug release from the MR component.
As noted above, the modified-release component has, in particular, an in vitro dissolution rate of 5 to 15 wt.% of furazidin within 2 h, based on the total furazidin content of the MR component. The aforementioned in vitro dissolution rate is determined by using European Pharmacopoeia edition 10 Apparatus Baskets “1” in 1000 mL volume of phosphate buffer solution of pH=6.8 with the addition of 2.5% CTAB (hexadecyltrimethylammonium bromide) at 37.0°C±0.5°C and 100 rpm. Preferably, the pH-independent polymer provides a MR component having an in vitro dissolution rate at each pH of 1.2, 4.5 and 7.4, which is within a range of ±10% of the respective in vitro dissolution rate at a pH of 6.8. The in vitro dissolution rate at a pH of 1.2, 4.5 or 7.4 is measured accordingly using a phosphate buffer solution of pH=4.5 or 7.4 with the addition of 2.5% CTAB or aqueous HC1 of pH=1.2 with the addition of 2.5% CTAB. The drug release from the MR component is thus pH-independent.
Preferably, the pH-independent polymer is at least one selected from the group consisting of hydroxypropylmethylcellulose (HPMC), hydroxyethylcellulose (HEC), hydroxypropylcellulose, methylcellulose (MC), xanthan gum, sodium carboxymethylcellulose, non-ionic poly(ethylene oxide), copovidone (vinylpyrrolidone-vinyl acetate copolymer), and any combination thereof. More preferably, the pH-independent polymer has a weight average molecular weight (Mw) of 50,000 to 7,000,000, preferably 350,000 to 800,000. Preferred
examples of hydroxypropylmethylcellulose (HPMC) have a weight average molecular weight of 70,000 to 1,000,000, preferably 70,000 to 600,000, more preferably 70,000 to 170,000. Preferred examples of carboxymethylcellulose (CMC) have a weight average molecular weight of 200,000 to 500,000, preferably 350,000 to 450,000, more preferably 370,000 to 400,000. Preferred examples of hydroxy ethylcellulose (HEC) have a weight average molecular weight of 50,000 to 200,000, preferably 80,000 to 150,000, more preferably 80,000 to 100,000. Preferred examples of methylcellulose (MC) have a weight average molecular weight of 12,000 to 280,000, preferably 10,000 to 220,000, more preferably 370,000 to 400,000. Preferred examples of copovidone have a weight average molecular weight of 50,000 to 100,000, preferably 45,000 to 70,000. The weight average molecular weights are measured by GPC/SEC according to EU Pharmacopoeia 5.0 method 2.2.30. In the modified-release component b), it is even more preferred if the pH-independent polymer is a combination of hydroxypropylmethylcellulose K4M and hydroxyethylcellulose such as Natrosol, a combination of hydroxypropylmethylcellulose K4M and non-ionic polyethylene oxide) such as Polyox 7 000 000, a combination of hydroxypropylmethylcellulose K4M and hydroxypropylmethylcellulose K100LV (Mw = 160,000 to 170,000, such as 164,000), a combination of hydroxypropylmethylcellulose K4M and hydroxypropylcellulose such as Klucel LF, a combination of hydroxypropylmethylcellulose K15M and xanthan gum such as Xantural 75, a combination of hydroxypropylmethylcellulose K15M and sodium carboxymethyl cellulose such as Blanose 7M31F, a combination of hydroxypropylmethylcellulose K15M and methylcellulose A4MP or A15CP, methylcellulose A4MP or A15CP, copovidone (vinylpyrrolidone- vinyl acetate copolymer) (e.g. Kollidon VA 64 and/or Plasdone S 630), or a combination of hydroxypropylmethylcellulose K15M and copovidone (e.g. Kollidon VA 64 and/or Plasdone S 630). Combinations of two pH- independent polymers are preferred for more adequately sustaining and controlling the furazidin release. Most preferably, a combination of hydroxypropylmethylcellulose K4M and hydroxy ethylcellulose is used as the pH-independent polymer.
Some of the pH-independent polymers can also serve as binders. In principle, such a compound can be used as both controlled-release agent and binder in the same pharmaceutical composition.
In the pharmaceutical composition, the immediate release component a) and the modified-release component b) each comprise at least one excipient. As the at least one excipient, the immediate release component a) may comprise at least one of a filler, a disintegrant, a binder, a lubricant, a glidant and any combination thereof. Preferably, the
immediate release component a) comprises a filler, a disintegrant, a glidant, a lubricant, and, optionally, a binder. The immediate release component a) preferably consists of furazidin and a filler, a disintegrant, a glidant, a lubricant, and, optionally, a binder. Preferably, a binder is also present in the immediate-release component a).
The modified-release component b) may comprise, as the at least one excipient, at least one of a filler, a disintegrant, a binder, a lubricant, a glidant and any combination thereof, preferably the modified-release component b) comprises a filler, a disintegrant, a binder, a lubricant, and, optionally, a glidant. The modified-release component b) preferably consists of furazidin, a controlled-release agent, a filler, a disintegrant, a binder, a lubricant, and, optionally, a glidant. More preferably, the MR component does not contain a glidant.
In the pharmaceutical composition, the immediate release component a) and/or, preferably and, the prolonged-release component b) comprise a filler. Herein, a filler means at least one filler. Accordingly, the filler may be at least one filler independently selected from the group consisting of anhydrous or monohydrate lactose, sucrose, microcrystalline cellulose, starch such as maize starch, pregelatinized starch, microcrystalline cellulose coated with colloidal silica, mannitol and any combination thereof. Preferably, the filler is at least one independently selected from the group consisting of anhydrous or monohydrate lactose, mannitol, microcrystalline cellulose, maize starch, saccharose and any combination thereof. More preferably, the filler is at least one selected from the group consisting of lactose monohydrate, microcrystalline cellulose, or a combination thereof. The immediate release component a) may contain the filler in an amount of 10 to 50 wt.%, preferably 10 to 30 wt.%, based on the weight of the immediate release component a). The modified-release component b) contains the filler in an amount of 10 to 45 wt.%, preferably 10 to 30 wt.%, based on the weight of the modified-release component b).
In the pharmaceutical composition, the immediate release component a) and/or the modified-release component b) comprise a binder. Preferably the immediate release component a) and the modified-release component b) comprise a binder, the binder being contained in addition to the controlled-release agent. Herein, a binder means at least one binder. Accordingly, the binder may, for example, be at least one binder independently selected from the group consisting of hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, carboxymethylcellulose, hydroxycellulose, hydroxyethylcellulose, polyvinyl alcohol, polyvinylpyrrolidone, copovidone, pregelatinized starch, gelatine and any combination thereof. Preferably, the binder is at least one independently selected from the group consisting of hydroxypropyl cellulose, polyvinylpyrrolidone and any combination thereof. More
preferably the binder is polyvinylpyrrolidone. The binder may be used in an amount equal to 0.4 to 5 wt.%, preferably 0.8 to 3 wt.%, more preferably 0.8 wt.%, based on the total mass of the composition. The immediate release component a) may contain the binder in an amount of 0.4 to 5 wt.%, preferably 0.4 to 3 wt.%, more preferably 0.5 wt.%, based on the weight of the immediate release component a). The modified-release component b) may contain the binder in an amount of 0.4 to 5 wt.%, preferably 0.4 to 3 wt.%, more preferably 0.9 wt.%, based on the weight of the modified-release component b). A binder is not required if the respective component is produced by dry granulation or direct compacting. It is however preferred to use wet granulation in the preparation of the components, where a binder is commonly used as described in more detail below.
In the pharmaceutical composition, the immediate release component a) and/or, preferably and, the modified-release component b) comprise a disintegrant. Herein, a disintegrant means at least one disintegrant. Accordingly, the disintegrant may, for example, be at least one disintegrant independently selected from the group consisting of carboxymethylcellulose sodium salt, sodium croscarmellose, microcrystalline cellulose, crospovidone, sodium starch glycolate, maize starch, and any combination thereof. Preferably, the disintegrant is at least one independently selected from the group consisting of sodium starch glycolate, sodium croscarmellose, maize starch and any combination thereof. More preferably, the disintegrant is sodium croscarmellose or sodium starch glycolate. The disintegrant may be used in an amount of 0.3 to 5 wt.%, preferably 1 to 4.5 wt.%, more preferably 3.6 wt.%, based on the total mass of the composition. The immediate release component a) may contain the disintegrant in an amount of 0.5 to 6 wt.%, preferably 2 to 6 wt.%, more preferably 5 wt.%, based on the weight of the immediate release component a). The modified-release component b) may contain the disintegrant in an amount of 0.3 to 5 wt.%, preferably 2 to 5 wt.%, more preferably 3 wt.%, based on the weight of the modified-release component b).
In the pharmaceutical composition, the immediate release component a) and/or, preferably and, the modified-release component b) comprise a lubricant. Herein, a lubricant means at least one lubricant. Accordingly, the lubricant may, for example, be at least one lubricant independently selected from the group consisting of stearic acid, magnesium stearate, calcium stearate, sodium stearyl fumarate, glycerol tristearate, palm oil derivatives such as palmitic acid or hydrogenated palm oil, especially Softisan 154, hydrogenated vegetable oil, such as hydrogenated castor oil, and any combination thereof. Preferably, the lubricant is at least one independently selected from magnesium stearate and stearic acid. The lubricant may
be used in an amount of 1 to 10 wt.%, preferably 2 to 4 wt.%, more preferably 1.3 to 1.4 wt.% such as 1.35 wt.%, based on the total mass of the composition. The immediate release component a) may contain the lubricant in an amount of 2 to 4 wt.%, preferably 2.3 wt.%, based on the weight of the immediate release component a). The modified-release component b) may contain the lubricant in an amount of 0.5 to 2 wt.%, preferably 1 wt.%, based on the weight of the modified-release component b).
In the pharmaceutical composition, the immediate release component a) and/or the modified-release component b) may comprise a glidant. It is preferred that the immediate release component a) but not the modified-release component b) comprises a glidant. Herein, a glidant means at least one glidant. Accordingly, the glidant may, for example, be at least one glidant independently selected from the group consisting of fumed silica (colloidal silicon dioxide), such as colloidal anhydrous silica, starch, talc and any combination thereof. Preferably, the glidant is colloidal anhydrous silica. The glidant may be used in an amount of 0.3 to 3 wt.%, preferably 0.4 to 2 wt.%, more preferably 0.46 wt.%, based on the total mass of the composition. The immediate release component a) may contain the glidant in an amount of 1.4 to 1.7 wt.%, preferably 1.6 wt.%, based on the weight of the immediate release component a). The modified-release component b) may contain the glidant in an amount of up to 1.3 wt.%, based on the weight of the modified-release component b).
According to a further embodiment of the pharmaceutical composition, the immediate release component a) and/or the modified-release component b) comprise at least one absorbent as an excipient. An absorbent may, for example, be added to the granulate of the IR component or the MR component or the extragranular fraction in order to stabilize moisture level and, thus, to improve the quality of the physical properties of the granulate and facilitate subsequent compression of the granulate to form a tablet. The absorbent provides stabilisation of moisture level and pH of the granulate and of the final composition. The absorbent is preferably pH- neutral. The absorbent may, for example, be selected from magnesium aluminometasilicates. Preferably, the absorbent is selected from one of the Neusilin grades, such as Neusilin US2® from Fuji Chemicals. In general, an absorbent is not required in the pharmaceutical composition.
Particularly preferred pharmaceutical compositions of the present invention are obtained by combining preferred embodiments such as preferred contents and preferred components.
For example, according to a particularly preferred embodiment, the pharmaceutical composition is a single dosage form in the form of a bilayer tablet, in which the immediate
release component a) forms a first layer, the modified-release component b) forms a second layer. The single dosage form of the pharmaceutical composition contains 150 to 250 mg of furazidin, preferably 180 to 220 mg of furazidin, and more preferably 200 mg of furazidin. The immediate release component a) comprises 35 to 55 mg, preferably 45 to 55 mg, more preferably 50 mg, of furazidin, and the modified-release component b) comprises 145 to 165 mg, preferably 145 to 155 mg, more preferably 150 mg, of furazidin. In the matrix of the modified-release component b), the modified-release component b) comprises 10 to 40 wt.%, preferably 10 to 35 wt.%, more preferably 20 to 30 wt.%, of a pH-independent polymer as the controlled-release agent, the pH-independent polymer being at least one selected from the group consisting of hydroxypropylmethylcellulose (HPMC), hydroxyethylcellulose (HEC), hydroxypropylcellulose, methylcellulose (MC), xanthan gum, sodium carboxymethylcellulose, non-ionic poly(ethylene oxide), copovidone (vinylpyrrolidone-vinyl acetate copolymer), and any combination thereof.
According to another particularly preferred embodiment, the immediate release component a) comprises 10 to 50 wt.%, preferably 10 to 30 wt.%, of a filler, 0.5 to 6 wt.%, preferably 2 to 6 wt.%, of a disintegrant, 1.4 to 1.7 wt.%, preferably 1.6 wt.%, of a glidant, 2 to
4 wt.%, preferably 2.3 wt.%, of a lubricant and, optionally, 0.4 to 5 wt.% of a binder, based on the total weight of the immediate release component a). The immediate release component a) may comprise 0.4 to 5 wt.%, preferably 0.4 to 3 wt.%, more preferably 0.5 wt.%, of a binder, based on the total weight of the immediate release component a). The filler, the disintegrant, the lubricant, the glidant and the binder are preferably selected from the above-mentioned compounds. The immediate release component a) may further contain 32 to 50 wt.%, preferably 41 to 50 wt.%, more preferably 45 to 46 wt.%, such as 45.45 wt.%, of furazidin and can consist of furazidin and the aforementioned excipients in the indicated amounts. Even more preferably, the immediate release component a) contains or consist of 45.5 wt.% of furazidin, 29.5 wt.% of microcrystalline cellulose, 5.0 wt.% of sodium starch glycolate, 15.6 wt.% of maize starch, 1.6 wt.% of colloidal anhydrous silica, 2.3 wt.% of stearic acid and 0.5 wt.% of polyvinylpyrrolidone, based on the total weight of the immediate release component a).
According to another particularly preferred embodiment, the modified-release component b) comprises 10 to 40 wt.%, preferably 10 to 35 wt.%, more preferably 20 to 30 wt.%, of the controlled-release agent, 10 to 45 wt.%, preferably 10 to 30 wt.%, of a filler, 0.3 to
5 wt.%, preferably 2 to 5 wt.%, more preferably 3 wt.%, of a disintegrant, 0.4 to 5 wt.%, preferably 0.9 wt.%, of a binder, 0.5 to 2 wt.%, preferably 1 wt.%, of a lubricant, and, optionally, up to 1.3 wt.% of a glidant, based on the total weight of the modified-release
component b). Preferably, it does not contain a glidant. The controlled-release agent, the filler, the disintegrant, the lubricant, the glidant and the binder are preferably selected from the above- mentioned compounds. The modified release component b) may further contain 40 to 60 wt.%, preferably 52 to 56 wt.%, more preferably 54 to 55 wt.%, such as 53.57 wt.%, of furazidin and can consist of furazidin and the consist of furazidin and the aforementioned excipients in the indicated amounts. Even more preferably, the modified-release component b) contains or consists of 53.6 wt.% of furazidin, 13.6 wt.% of lactose monohydrate, 19.7 wt.% of hydroxypropylmethylcellulose K4M, 8.2 wt.% of hydroxy ethylcellulose, 3 wt.% of croscarmellose sodium, 1.0 wt.% of magnesium stearate and 0.9 wt.% of polyvinylpyrrolidone, based on the total weight of the immediate release component b).
In a preferred variant of the pharmaceutical composition, the IR component and MR component form a bilayer tablet and the MR component contains pH-independent polymer matrix allowing for the modified release of furazidin. The modified release of furazidin may be further characterized by the thickness of the pH-independent-polymer matrix after swelling, i.e. in the swollen state. After immersing the modified-release component b) in 30 to 35 mL of phosphate buffer of pH=4.5 for 2 hours, the buffer being contained in a beaker, heated by a wiggled, heated bath at 37°C, the matrix of the modified-release component b) is in a swollen state and has a thickness in the range of 4.1 to 6.6 mm, preferably 4.9 to 5.5 mm. The thickness measurements are performed on the MR component, swollen in a medium resembling fed conditions in vivo. Such a thickness of the swollen MR component is favourable for obtaining a controlled release of furazidin from the pH-independent polymer matrix and absorption in the upper part of the small intestine in order to obtain a desirable time/concentration profile of furazidin. Pharmacokinetics studies (PK phase I studies) showed that furazidin in form of a prolonged release composition according to the present invention is mainly absorbed in the upper part of the small intestine. Before swelling, the dry modified-release component has a thickness in the range of 3.0 to 5.0 mm, preferably 3.5 - 4.0 mm. The thickness ratio of the thickness of the modified-release component b) in the swollen state to the thickness of the dry modified-release component b) before swelling is in the range of 1.1 to 1.8, preferably 1.3 to 1.6.
As outlined above, the pharmaceutical composition of the present invention provides preferable pharmacokinetics as a controlled, preferably constant, release of furazidin is achieved. The pharmacokinetics obtained with the pharmaceutical composition of the present invention differ fundamentally from prior art furazidin compositions for the treatment of UTI, which basically show an immediate release of furazidin. The preferable pharmacokinetics allow
for reducing the dosage frequency in the treatment of UTI, thus improving patients’ compliance and convenience and ensuring a better therapeutic efficacy.
According to a preferred embodiment, the pharmaceutical composition is a single dosage form, in particular in the form of a bilayer tablet, and configured to provide, after oral administration, a maximum plasma concentration of furazidin (Cmax) of 353.1±122.5 ng/mL after tmax of 2.5±0.5 hours after administration, and an area under the plasma concentrationtime curve from time zero to 24 hours (AUC0-24) of 1404.1±392.8 ng h/mL, as determined by human PK studies. Furthermore, the pharmaceutical composition may be configured to provide, after oral administration of a single dosage form, in particular in the form of a bilayer tablet, of the pharmaceutical composition twice a day and 12 hours apart for 3 days, a maximum plasma concentration in steady state (Cmax,ss) of furazidin of 516.4±149.3 ng/mL and an area under the plasma concentration-time curve from time zero to 24 hours in steady state (AUCo-24,ss) of 3498.1±932.2 ng h/mL, as determined by human PK studies.
Preferably the pharmaceutical composition of the present invention is a single dosage form and has an in vitro dissolution rate of furazidin of 10 to 40 wt.%, preferably 10 to 30 %, within 1 h, 40 to 65 wt.% within 6 h and above 80 wt.% within 14 h, based on the total furazidin content of the single dosage form, as determined by using European Pharmacopoeia edition 10 Apparatus Baskets “1” in 1000 mL volume of phosphate buffer solution of pH=6.8 with the addition of 2.5% CTAB (hexadecyltrimethylammonium bromide) at 37.0°C±0.5°C and 100 rpm.
In another aspect, the invention relates to the method of manufacturing the prolonged- release pharmaceutical composition. The method enables the production of the pharmaceutical composition using conventional tools and well-known pharmaceutical technologies, while significantly simplifying the manufacturing process, and reducing its costs comparing to manufacturing standards known in the art. The pharmaceutical composition, in particular in the form of a bilayer tablet, can be prepared by a method comprising direct compression, dry granulation or wet granulation for making the immediate-release component and the modified- release component b).
Thus, a method of manufacturing the prolonged-release pharmaceutical composition comprises (a) a step of preparing the immediate release component a); (b) a step of preparing the modified-release component b); (c) a step of combining the immediate release component a) and the modified-release component (b) to form a bilayer tablet, in which the immediate release component a) forms a first layer, the modified-release component (b) forms a second
layer; and, optionally, (d) a step of forming a coating around the first and second layers obtained in step (c). Preferably, no coating is formed, that is, step (d) is preferably not carried out.
In step (a) and step (b), the IR component and MR component may be independently prepared using a dry or wet technology such as dry or wet granulation.
A dry-granulated IR component or MR component can be obtained using direct dry granulation of a powder mixture comprising furazidin or a pharmaceutically acceptable salt thereof, suitable excipients as described above and, in case of the MR component, a controlled- release agent, as described above, in particular at least one pH-independent polymer. Other excipients can be also included, if needed. Suitable excipients, used in pharmacy, can be found in the „Handbook of Pharmaceutical Excipients" edited by R. C. Rowe, P. J. Sheskey, and S. Owen, Pharmaceutical Press, edition VII. The dry granulation method used to obtain the IR component (step (a)) or the MR component (step (b)) can be selected from roller compaction and slugging. Methods known to the skilled person and are described, for example, in the “Pharmaceutical Manufacturing Handbook" edited by Shayne Cox Gad, published by John Wiley & Sons, Inc., Hoboken, New Jersey.
A wet-granulated IR component or MR component can be obtained using a suitable granulation method known in the art using powder mixtures comprising furazidin or a pharmaceutically acceptable salt thereof, suitable excipients as described above and, in case of the MR component, a controlled-release agent, as described above, in particular at least one pH-independent polymer. Other excipients can be also included, if needed. The wet granulation method used to obtain the IR component (step (a)) or the MR component (step (b)) can be selected from low shear, high shear, and fluid bed granulation. Preferably, the IR component and the MR component are obtained by wet granulation (steps (a) and (b)).
Blending operations can be performed in a suitable blender, preferably in a container blender.
According to an embodiment of the method, the IR component a) and/or the MR component b) are prepared using dry granulation (steps (a) and (b)). In such a variant, the method preferably comprises the following steps: (I) blending furazidin or a pharmaceutically acceptable salt thereof with all excipients except lubricant and, in case of the MR component, with the at least one controlled-release agent to homogeneity; II) adding a part of the lubricant and subsequent blending; III) dry granulation by roller-compaction or slugging; IV) breakingdown the resulting slugs or sheets using a milling technique to produce granules; V) adding the remaining part of lubricant and subsequent blending.
In the dry methods of granulation, the primary powder blend particles are aggregated under high pressure using one of two main dry granulation processes: either roller-compaction or slugging. In both cases the intermediate products, slugs or sheets, are broken down using a suitable milling technique to produce granular material, which can be additionally sieved to separate the desired size fraction. Such a way of processing a furazidin powder blend is very advantageous for several reasons. It allows for the elimination of water, which may affect furazidin stability, and obtaining a granulate having grain sizes that are optimal for further processing (combination with the second component comprising furazidin and optional extragranular phase component without the effect of physical segregation). Additionally, a broad ratio (wt.%) of furazidin can be blended into the dry granulate intermediate, which is not possible in other dry pharmaceutical processes (e.g. direct compression).
According to another embodiment of the method, the IR component a) and/or the MR component b) are prepared using wet granulation (steps (a) and (b)). In such a variant, the method preferably comprises the following steps: I) mixing of furazidin or a pharmaceutically acceptable salt thereof with at least one filler, at least one disintegrant, optionally further excipients, and, in case of the MR component, at least one controlled-release agent in a high- shear granulator to homogeneity; II) granulating the mixture of step I) by addition of a binder solution in water or another processing agent, such as an alcohol, e.g. ethanol, or with a mixture thereof; III) drying and unifying the dried granule sizes by sieving or screening; and, optionally, IV) adding an extragranular phase comprising lubricant and/or a mixture of filler and glidant and/or an absorbent and a glidant.
Furazidin may be also subjected to a process of wet granulation (e.g. low shear, high shear or in a fluidized bed), to improve its solubility. Wet granulation facilitates obtaining the desired in vitro and in vivo release profiles. The resulting wet granulate is dried and, for example, screened to obtain a proper distribution of the particles, allowing a durable combination with the other component and additional excipients.
According to a preferred embodiment of the method, the IR component a) is prepared using dry granulation (step (a)), and the MR component b) is prepared using wet granulation (step (b)). It is also preferred to prepare the IR component (step (a) and the MR component (step (b)) by wet granulation.
In step (c) of the method, the resulting components a) and b) are combined together, and depending on the desired final form, for example, compressed into separate layers in a tablet, optionally followed by forming a coating in step (d), resulting in a single unit dosage form.
Preferably, the prolonged-release pharmaceutical composition is prepared by using a bilayer tableting technology in step (c).
According to another aspect, the present invention provides a method of treating UTI using a pharmaceutical composition as described herein above. Thus, the present invention provides a pharmaceutical composition as described herein above for use in a method of treatment of a urinary tract infection. The urinary tract infection is preferably an acute or recurrent uncomplicated urinary tract infection, for example caused by Escherichia coH. such as recurrent uncomplicated urinary tract infection in women caused by Escherichia coli.
According to an embodiment, the pharmaceutical composition is a single dosage form, such as a bilayer tablet, which is administered orally two times daily, preferably 11 to 13 hours apart, more preferably 12 hours apart. Typically, the pharmaceutical composition is administered for 5 to 8 days, preferably 7 days. This regimen has the advantage of better patients’ compliance and improved quality of life during therapy in comparison to the treatment of UCI using a prior art furazidin composition. In conventional therapies, the high dosages of furazidin require large dosage forms, with the necessity of taking 2 or 4 tablets, depending on the available presentation, at once 3 or 4 times daily for 7 up to 10 days.
Typically, the pharmaceutical composition is administered in combination with a meal, as absorption of furazidin is improved. In combination with a meal means that the pharmaceutical composition is taken shortly before, together with or after the meal. It is thus preferred that the pharmaceutical composition is a single dosage form, which is administered orally within an interval of from 30 min before a meal and 30 min after a meal. Preferably, the pharmaceutical composition is administered between at a meal and 30 min after a meal, and more preferably, right after the meal, that is, within 5 min after a meal.
For oral administration two times a day, a single dosage form of the pharmaceutical composition usually contains 150 to 250 mg of furazidin, preferably 180 to 220 mg of furazidin, and more preferably 200 mg of furazidin. In particular, the immediate release component a) comprises 35 to 55 mg, preferably 45 to 55 mg, more preferably 50 mg, of furazidin, and the modified-release component b) comprises 145 to 165 mg, preferably 145 to 155 mg, more preferably 150 mg, of furazidin. In a particularly preferred variant, 200 mg of furazidin formulated as a fixed dose comprising 50 mg of furazidin in IR component and 150 mg of furazidin in MR component is administered, 2 times daily, for example, for 7 days.
It is an advantage of the present invention that the prolonged-release furazidin composition provides continuous furazidin effective concentration levels during the whole
period of treatment, especially during the night. This effect could not be achieved with the use of a prior art immediate release formulation, which provides effective concentrations only during a short period of time after administration. Consequently, continuous bacteriostatic concentration in serum and urine could not be provided, which is however crucial for effective therapy.
The method of treatment according to the present invention thus provides favourable furazidin pharmacokinetics, which are not obtained by prior art furazidin compositions. Preferably, wherein oral administration of one single dosage form of the pharmaceutical composition provides a maximum plasma concentration of furazidin (Cmax) of 353.1±122.5 ng/mL after tmax of 2.5±0.5 hours after administration, and an area under the plasma concentration-time curve from time zero to 24 hours (AUC0-24) of 1404.1±392.8 ng h/mL, as determined by human PK studies described below. It is further preferred that oral administration of a single dosage form of the pharmaceutical composition twice a day and 12 hours apart provides after 3 days a maximum plasma concentration in steady state (Cmax,ss) of furazidin of 516.4±149.3 ng/mL and an area under the plasma concentration-time curve from time zero to 24 hours in steady state (AUCo-24,ss) of 3498.1±932.2 ng h/mL, as determined by human PK studies as described below.
Brief description of the drawings
Fig. 1 shows the pharmacokinetic profiles of means in plasma of the food effect study of Example 5.
Fig. 2 shows the pharmacokinetic profiles of means in urine of the food effect study of Example 5.
Fig. 3 shows the pharmacokinetic profile of means in plasma of the multiple-dose study of Example 6.
Fig. 4 shows the pharmacokinetic profile of means in urine of the multiple-dose study of Example 6.
Examples
Example 1. Preparation of IR component, MR component and pharmaceutical composition
Exemplary IR components (IR/1 to IR/4) and MR components (MR/1 to MR/15) according to the present invention are presented in the Tables 1 and 2 below.
Table 1. Compositions of exemplary IR components
Table 2. Compositions of exemplary MR components
Table 2 (continued). Composition of exemplary MR components
In the following procedures, the amounts of the components were used as specified in Tables 1 and 2.
Preparation of granulate of immediate release component
The IR components IR/1 and IR/2 are prepared as follows:
1. Weighing of furazidin, microcrystalline cellulose 102, sodium starch glycolate, povidone 90, maize starch, colloidal anhydrous silica, stearic acid (i.e. furazidin, filler, disintegrant, binder, glidant, lubricant).
2. Mixing furazidin, microcrystalline cellulose 102, sodium starch glycolate, a part of the maize starch (72 wt.%), in a high shear granulator (i.e. furazidin, filler, disintegrant).
3. Preparation of the binder solution: Povidone 90, purified water (i.e. binder, processing agent)
4. Wet granulation using the mixture from step 2 and the binder solution from step 3 is performed in a High Shear Granulator. Granulation time 1 to 3 min. Appearance of the wet blend was assessed by squeezing the mass.
5. Wet-sizing of the granulate obtained in step 4 in a sizing machine, IPC - Screen size 3 to 6 mm.
6. Drying of the seized granulate obtained step 5 in a fluid bed dryer at a temperature of max. 55°C, accepted levels of LOD are in a range of 1 to 3%.
7. Sizing of the granulate obtained in step 6 in a sizing machine , IPC - Screen size 1 mm
8. Weighing of the remaining part of the maize starch (28 wt.%), colloidal anhydrous silica, stearic acid (i.e. filler, lubricant, glidant).
9. Blending the granulate obtained in step 7 with the part of maize starch, colloidal anhydrous silica (i.e. filler, glidant) after sizing.
10. Blending the sized granulate from step 9 with stearic acid (lubricant) in a bin blender. Blending time 3 to 5 min.
The IR components IR/3 and IR/4 are prepared as follows:
1. Weighing of furazidin, microcrystalline cellulose 102 or saccharose, maize starch, colloidal anhydrous silica, stearic acid (i.e. furazidin, filler, disintegrant, glidant, lubricant).
2. Blending all the components from step 1 except of the lubricant.
3. Blending the blend obtained in step 2 with the lubricant.
4. Tabletting on a tablet press.
Preparation of granulate of modified release component
The MR components MR/1 to MR/15 are prepared as follows:
1. Weighing of furazidin, lactose monohydrate, hypromellose K4M, povidone 90, hydroxyethylcellulose 250L, croscarmellose sodium, magnesium stearate or corresponding compounds indicated in Table 2 (i.e. furazidin, filler, control release agent, binder, lubricant and disintegrant).
2. Mixing furazidin, lactose monohydrate, hypromellose K4M, hydroxyethylcellulose 250L, croscarmellose sodium or the corresponding compounds (i.e. furazidin, filler, control release agent and disintegrant) in a high shear granulator.
3. Preparation of the binder solution: Povidone 90, purified water, ethanol (i.e. binder and processing agents)
4. Wet Granulation using the mixture from step 2 and the binder solution from step 3 is performed in a high shear granulator. Granulation time 1 to 3 min. Appearance of the wet blend was assessed by squeezing the mass.
5. Wet-sizing of the granulate obtained in step 4 in a sizing machine, IPC - Screen size 3 to 6 mm.
6. Drying of the seized granulate obtained in step 5 in a fluid bed dryer at a temperature of max. 55°C, accepted levels of LOD are in a range of 1 to 3%.
7. Blending of the sized granulate from step 6 with magnesium stearate (lubricant) in a bin blender. Blending time 3 to 5 min.
Preparation of bilayer tablets
The final blend granulates are compressed into bilayer-tablets with the aid of rotary press machine. During the compression process, the following requirements of the tablets should be satisfied (Table 3).
Table 3. Requirements during compression process
For the pharmaceutical composition IR/l+MR/1, the above processes were used to prepare a batch of bilayer tablets using 46 kg of the granulate of the modified-release component and 18 kg of the granulate of immediate release component.
Example 2. Dissolution studies
As prolonged-release pharmaceutical composition, a bilayer tablet having the composition of IR/l+MR/1 (in total 200 mg furazidin) was used. Dissolution testing was performed using the following conditions:
Apparatus: Baskets “1”
Media volume: 1000 mL
Temperature: 37.0°C ± 0.5°C
Speed: 100 rpm
Sampling times: 0.5, 1, 2, 4, 6, 8, 10, 12 and 14 hours
Medium: phosphate buffer solution pH=6.8 with addition of 2.5% CTAB (hexadecyltrimethylammonium bromide)
The quantities of drug substance released from the tested tablets are determined by HPLC. The mean value calculated from 6 tablets are indicated in Table 4.
Table 4. Dissolution data (mean value calculated from 6 tablets), pH=6.8
The following Table 5-1 shows dissolution results of selected MR components at a pH of 6.8. Tables 5-2 to 5-4 show dissolution results of selected MR components at a pH of 4.5 or 7.4 using a corresponding phosphate buffer solution containing 2.5% CTAB, and pH = 1.2 using an aqueous HC1 containing 2.5% CTAB. The MR components were pressed to tablets and subjected to a dissolution test using the above conditions. The sampling times are indicated in Tables 5-1 to 5-4. The mean value calculated from 6 samples is indicated.
le 5-1. Dissolution data for exemplary MR components, pH=6.8
Table 5-2. Dissolution data for exemplary MR components, pH=4.5
le 5-3. Dissolution data for exemplary MR components, pH=7.4
ble 5-4. Dissolution data for exemplary MR components, pH=1.2
Example 3. Swelling test - analysis of the MR matrix texture
In Example 3, the swelling properties of the MR component having a pH-independent polymer matrix and the dissolution of furazidin from the MR component were investigated. For the swelling test, the samples were prepared as follows. The test time and conditions are adjusted as to achieve complete dissolution of the IR layer and mimic the swelling characteristics of the MR component after 2 h mean retention time of the tested tablet in the stomach a after meal.
Sample preparation: Tablets, having the composition indicated in Tables 6-1 to 6-4 below, were produced as described above in Example 1. The tablets (n=5) were placed in a beaker filled with 30 to 35 mL of phosphate buffer of pH = 4.5, 6.8 or 7.4 and 0.1M HC1 of pH = 1.2, respectively. The beaker is placed in wiggled, heated bath at a temperature of 37°C. The tablets are incubated for 2 hours.
The swollen samples were tested using a common texture analyser. Before testing, the probe of the texture analyser was calibrated against the testing platform (i.e. a blank slide).
After the IR component (if present) of the tablet was completely dissolved (completion after 2 h incubation), the swollen MR component (i.e. the MR component is the swollen state) of the tablets was transferred from the beaker on slides and singly tested.
For the data analysis, the values of interest for a sample were obtained by a macro included in the software of the TA.XTplus Texture Analyser. The macro quantifies the measured gel thickness. The average of 5 tablets was calculated. The results are summarized in Table 6 indicating the thickness of the MR component before swelling, the thickness range of the individual results after swelling, the average thickness after swelling and the swelling ratio (thickness before swelling/thickness in the swollen state).
The following settings were used:
Instrum ent/software: TA.XTplus Texture Analyser (Stable Micro Systems Ltd)/Exponent Accessory: Load cell - 5 kg
Cylinder probe
TA settings: Mode: Measure Distance in Compression
Pre-Test Speed: l.O mm/s
Test speed: 0.1 mm/s
Post-Test Speed: 5.0 mm/s
Target Mode: Force
Table 6-1. Thickness of the initial and swollen MR component and swelling ratio of the MR component after 2h incubation in phosphate buffer, pH=4.5
Table 6-2. Thickness of the initial and swollen MR component and swelling ratio of the MR component after 2h incubation in aqueous HC1, pH=1.2
Table 6-3. Thickness of the initial and swollen MR component and swelling ratio of the MR component after 2h incubation in phosphate buffer, pH=6.8
Table 6-4. Thickness of the initial and swollen MR component and swelling ratio of the MR component after 2h incubation in phosphate buffer, pH=7.4
The dissolution amount of furazidin has been determined according to the dissolution test in Example 2. The mean values for several tablets are indicated in Table 7.
Table 7. Dissolution amount of furazidin after 2 h under the conditions of Example 2.
It was found that the thickness of the swollen MR component correlated with the dissolution profile of tablets composed of IR component and MR component as well as of the dissolution profile of the MR component alone.
The 2h time point has been chosen as representative for the correlation and referent for the prediction of the required full dissolution profile. The dissolution values at the representative 2h time point showed a release of furazidin on the level of about 20 to 30 wt.% (a range of 10 to 35 wt.% is acceptable for a prolonged-release composition) for the bilayer tablets composed of IR component and MR component and a release of furazidin on the level of about 7 wt.% (a range of 5 to 15 wt.% was considered acceptable) for the MR component MR/3 when tested alone. It was found that the results are consistent with the expected levels of released furazidin over time to provide appropriate PK values in vivo.
Example 4. Stability studies
Medicines must comply with the requirements of the chemical purity immediately after preparation (comply with the limits indicated in the release specification of the drug product), and within the period set by the relevant guidelines in time and storage conditions (comply with the limits indicated in the shelf-life specification of the drug product). The stability studies have been performed according to guideline CPMP/ICH/2736/99-ICH QI A (R2) Stability Testing of New Drug Substances and Products. The main impurity of furazidin is ACRO, i.e. (2E)-3-(5-nitro-2-furylo)acrylaldehyde.
The final composition was packed in blisters, SBC 180/aluminum foil, and stored at long term (25°C/60% RH), intermediate (30°C/65% RH) and accelerated (40°C/75% RH) conditions. The level of impurities and the content of active substance were determined by HPLC according to the method disclosed in Journal of Pharmaceutical and Biomedical Analysis, Vol. 129 (2016), 433-440. The results are presented in Tables 8, 9 and 10. Table 8. Stability under long term conditions (25°C, 60% RH).
lrThe requirements for the parameters tested during the stability study were established according to guidelines CPMP/ICH/367/96 (ICH Q6A), and CPMP/ICH/2738/99 (ICH Q3B (R2)).
Table 9. Stability under intermediate conditions (30°C, 65% RH).
lrThe requirements for the parameters tested during the stability study were established according to guidelines CPMP/ICH/367/96 (ICH Q6A), and CPMP/ICH/2738/99 (ICH Q3B (R2)).
Table 10. Stability under enhanced conditions (40°C, 75% RH).
lrThe requirements for the parameters tested during the stability study were established according to guidelines CPMP/ICH/367/96 (ICH Q6A), and CPMP/ICH/2738/99 (ICH Q3B (R2)).
Example 5. Phase I Clinical Trial Pivotal food effect study FUR-PK-03-19 (755/19) Study title: Randomized, open-label, three-period, cross-over, food effect pharmacokinetic study comparing bioavailability of furazidin, prolonged-release tablets, 200 mg having a composition of IR/l+MR/1 according to Example 1 in healthy subjects in different fed conditions.
Aim of the study: The main study objective was to evaluate the pharmacokinetic properties and to compare the bioavailability of the Test product in healthy volunteers under different fed conditions.
Study conduct: In this bioavailability study, the pharmacokinetic profile was tested for the Test formulation (prolonged-release bilayer tablet, IR/l+MR/1) having a strength of 200 mg furazidin. The bioavailability study was carried out under different fed conditions (after a high-protein meal or after a high-fat, high-calorie meal) and in fasting state in 30 healthy subjects. On the day of dosing, the subjects received randomly after an overnight fast a single dose of the modified-release formulation, administered on empty stomach (fasting conditions, Treatment A) or after a high-protein meal (Treatment B) or after a high-fat, high-calorie meal (Treatment C), each time with 240 mL of water. For each subject, there were 3 dosing periods, separated by a washout period of 7 days. Blood and urine samples were collected over 24 hours (20 blood samples and 9 urine samples). The results are shown in Tables 11 to 13 and Fig. 1 for the plasma analyses and in Tables 14 to 16 and Fig. 2 for the urine analyses.
The pharmacokinetic data for plasma and urine were statistically analysed in 29 subjects. After single oral administration of furazidin, prolonged-release formulation, 200 mg to the healthy volunteers, peak plasma concentrations were reached at 2 hours (median) following administration under recommended fed conditions (high-protein meal). Cmax and AUCO-24 reached 353.1±122.5 ng/mL and 1404.1±392.8 ng*h/mL, respectively. Plasma concentrations of furazidin showed a mean terminal half-life of 1.0 hour in healthy subjects. The mean urine concentrations of furazidin under recommended fed conditions achieved 9971.867± 3145.830 pg for Aeo-t and 1933.965±841.315 pg/h for Rmax. Peak urine concentrations were reached at 5 hours.
Total exposure (AUC) increases approximately 2 to 2.5-fold after high-protein and after high-fat, high calorie meal respectively compared to the fasting state, while Cmax is increased to a lower extent. The exposure after a high fat, high calorie meal increases approximately 25% compared to the exposure after high-protein meal. Largest difference in exposure after meals versus fasting state is observed after 6 hours (AUC(6-24)), which implies a difference in profile shape resulting from a much larger increase in exposure at later times post dosing. High-fat, high calorie meal increases the exposure from 6 to 24 hours about 5.6- fold. Coadministration of the modified-release formulation with a high-protein meal increases overall plasma and urine levels in the same way as it was observed for the immediate release product (Furaginum Adamed 50 mg tablets). Higher exposures observed after a high-fat,
high-calorie meal do not appear related to dose dumping. Dose dumping related to formulation failure would result in higher Cmax and exposures in the first four hours of the plasma concentration curves. Differences in profile shape between high-fat and high-protein administration are only observed in a subgroup of volunteers due to peaks occurring after 6 5 hours post dose, but it does not appear to be a formulation related issue because of the timing of differences.
Safety Results: Seven (7) subjects experienced a total of two (2) mild and seven (7) moderate adverse events (AE). In total, two adverse events were considered related to the oral administration of the Test product under fasting condition (Treatment A), i.e. one episode of 10 mild nausea (and vomiting) and one episode of moderate pyrosis (heartburn). No adverse event was considered related to the oral administration of the Test product in fed condition, high-protein breakfast (Treatment B). One (1) adverse event was considered related to the oral administration of the Test product under fed condition, high-calorie/high-fat breakfast (Treatment C), i.e., one episode of moderate nausea (and vomiting). No serious adverse event 15 (SAE) occurred during the Study.
Table 11. Pharmacokinetic parameters in plasma of furazidin - high protein vs fasting conditions
AUCo-t area under the plasma concentration-time curve calculated from time zero until the last measurable plasma concentration
AUCII- , area under the plasma concentration-time curve from time zero to infinity
AUCo-«h area under the plasma concentration-time curve from time zero to 6 hours
AUCsh-t area under the plasma concentration-time curve from time 6h to last measurable plasma concentration
AUCo-12 area under the plasma concentration-time curve from time zero to 12 hours
Cmax maximum plasma concentration tmax time for maximum concentration ti/2 half-life a arithmetic mean ± SD b In-transformed values c median, range
Table 12. Pharmacokinetic parameters in plasma of furazidin - high calorie/high fat vs fasting conditions
AUCo-t area under the plasma concentration-time curve calculated from time zero until the last measurable plasma concentration
AUCII- , area under the plasma concentration-time curve from time zero to infinity
AUCo-«h area under the plasma concentration-time curve from time zero to 6 hours
AUCsh-t area under the plasma concentration-time curve from time 6h to last measurable plasma concentration
AUCo-12 area under the plasma concentration-time curve from time zero to 12 hours
Cmax maximum plasma concentration tmax time for maximum concentration ti/2 half-life a arithmetic mean ± SD b In-transformed values c median, range
Table 13. Pharmacokinetic parameters in plasma of furazidin - high protein vs high calorie/high fat conditions
AUCo-t area under the plasma concentration-time curve calculated from time zero until the last measurable plasma concentration
AUCn- , area under the plasma concentration-time curve from time zero to infinity
AUCo-«h area under the plasma concentration-time curve from time zero to 6 hours
AUCsh-t area under the plasma concentration-time curve from time 6h to last measurable plasma concentration
AUCo-12 area under the plasma concentration-time curve from time zero to 12 hours
Cmax maximum plasma concentration tmax time for maximum concentration ti/2 half-life a arithmetic mean ± SD b In-transformed values c median, range
Fig. 1 shows the pharmacokinetic profiles of means (N=29) in plasma under fasting conditions (Treatment A), under fed conditions of a high-protein breakfast (Treatment B) and under fed conditions of a high-calorie/high-fat breakfast (Treatment C).
Table 14. Pharmacokinetic parameters in urine of furazidin - high protein vs fasting conditions
AURC(o-t) Area under the urine excretion rate-time curve to the last measurable excretion rate
AURCdi-,) Area under the urine excretion rate-time curve extrapolated to infinity, based on the last observed excretion rate
Aeo-t amount of unchanged drug excreted into the urine calculated as area under the urinary excretion rate curve from time zero to the last measurable rate
Rmax the maximum rate of drug excretion observed tmax time of maximum urinary excretion rate tl/2 half-life a arithmetic mean ± SD b In-transformed values c median, range
Table 15. Pharmacokinetic parameters in urine of furazidin - high calorie/high fat vs fasting conditions
AURC(o-t) Area under the urine excretion rate-time curve to the last measurable excretion rate
AURCdi-,) Area under the urine excretion rate-time curve extrapolated to infinity, based on the last observed excretion rate
Aeo-t amount of unchanged drug excreted into the urine calculated as area under the urinary excretion rate curve from time zero to the last measurable rate
Rmax the maximum rate of drug excretion observed tmax time of maximum urinary excretion rate ti/2 half-life arithmetic mean ± SD
In-transformed values c median, range
Table 16. Pharmacokinetic parameters in urine of furazidin - high protein vs high calorie/high fat conditions
AURC(o-t) Area under the urine excretion rate-time curve to the last measurable excretion rate
AU RCdi- , ) Area under the urine excretion rate-time curve extrapolated to infinity, based on the last observed excretion rate
Aeo-t amount of unchanged drug excreted into the urine calculated as area under the urinary excretion rate curve from time zero to the last measurable rate
Rmax the maximum rate of drug excretion observed tmax time of maximum urinary excretion rate ti/2 half-life arithmetic mean ± SD
In-transformed values c median, range
Fig. 2 shows the pharmacokinetic profiles of means (N=29) in urine under fasting conditions (Treatment A), under fed conditions of a high-protein breakfast (Treatment B) and under fed conditions of a high-calorie/high-fat breakfast (Treatment C).
Conclusions:
- Bioavailability was found to be 1.9-fold higher after high-protein meal and 2.5-fold higher after high-calorie/high-fat meal than under fasting conditions, (i.e. bioavailability after high- protein meal is about 25% lower than after high-calorie/high-fat meal). - Peak plasma concentration was found to be 1.4-fold higher after high-protein meal and 1.7- fold higher after high calorie/high-fat meal than under fasting conditions, (i.e. peak plasma concentration after high-protein meal is about 19% lower than after high-calorie/high-fat meal).
- Excreted amount of unchanged drug was found 1.9-fold higher after high-protein meal and 2.5-fold higher after high-calorie/high-fat meal than under fasting conditions, (i.e. excreted amount of unchanged drug after high-protein meal is about 25% lower than after high- calorie/high-fat meal).
- Urine excretion rate was found 1.4-fold higher after high-protein meal and 1.6-fold higher after high-calorie/high-fat meal than under fasting conditions, (i.e. urine excretion rate after high-protein meal is about 13% lower than after high-calorie/high-fat meal).
- The 90% confidence intervals for fedl*/fast, fed2*/fast and fedl*/fed2* ratios of LSM, based on In-transformed data of AUC(o-t) and Cmax were not found within the equivalence limits of 80.00-125.00 %. Hence, a significant food effect was confirmed.
- In general, a 25% increase in exposure after high-fat, high-calorie meal should not translate to a different safety profile, unless the drug has a narrow therapeutic index, which is not the case for the well-established drug substance furazidin.
- Furazidin administered orally should be taken at or after meals as this increases its bioavailability irrespective of the formulation or mechanisms of the drug release (MR or IR). Differences in concentrations after high-protein meal and after high-fat, high-calorie meal are statistically significant.
Example 6. Pivotal multiple-dose study FVR-PK-04-19 (759/19)
Study title: Randomized, open-label, two-period, multiple dose, cross-over, pivotal pharmacokinetic study comparing bioavailability of Furazidin, prolonged-release tablets, 200 mg of the composition IR/l+MR/1 according to Example 1 and Furaginum Adamed 50 mg, tablets in healthy male and female subjects under fed (high-protein meal) conditions.
Aim of the study: The main study objective was to evaluate the pharmacokinetic properties and to compare the bioavailability of furazidin after multiple-dose administration of the Test product versus the Comparator product in healthy male and female volunteers under fed (high-protein meal) conditions.
Study conduct: Thirty (30) subjects were included into the study. The elimination half-life of prolonged-release furazidin is about 1 hour. The elimination half-life reported in literature for immediate-release furazidin is no longer than 7 hours. In plasma, steady-state can be achieved within 1 to 2 days of twice-daily dosing of 200 mg prolonged-release furazidin tablets according to the present invention and three times daily dosing of 100 mg immediate-release furazidin tablets, respectively, so as to demonstrate that steady state has been reached when five (5) doses of furazidin, prolonged-release tablet, 200 mg according to the present invention and seven (7) doses of Furaginum Adamed, 50 mg, tablets were administered orally on Day 1 through Day 3. Dosing on Day 3 was continued up to 6 doses in total of prolonged- release tablets and, in total, 9 doses of immediate-release tablets to compare the total exposure after multiple dose administration.
Multiple oral doses of the Test product (6 doses) administered orally with 240 mL of water under fed (high-protein meal) conditions. Oral administration of one tablet given two
times a day (12 hours interval apart). Total dose per day was 400 mg of furazidin. Dosing for 3 consecutive days (on Day 1, Day 2 and Day 3 twice a day). Multiple oral dose of Comparator product (9 doses) administered orally with 240 mL of water under fed (high- protein meal) conditions.
Oral administration of two tablets given at the same time (2 x 50 mg) three times a day (8 hours interval apart). Total dose per day was 300 mg of furazidin. Dosing for 3 consecutive days (on Day 1, Day 2 and Day 3 three times a day).
The washout period was at least 7 days between the last dose in Period 1 and the first dose in Period 2. Blood samples were collected throughout a 76-hour period after the first IMP administration to characterize products absorption and elimination. Urine samples were collected over 24 hours post first dose on Day 1-Day 2 and over 28 hours post the first dose on Day 3 -Day 4.
Twenty -nine (29) subjects completed the study, and the data was used for the statistical analysis. Pharmacokinetic parameters were calculated from plasma and urine concentrations determined by a validated HPLC/MS/MS method for furazidin according to the method disclosed in Journal of Pharmaceutical and Biomedical Analysis, Vol. 129 (2016), 433-440. Pharmacokinetic parameters of the Test and the Comparator products were compared. The 90% confidence intervals for the Test to Comparator ratios were evaluated for the following pharmacokinetic parameters, which were considered as primary for bioavailability assessment:
Day 1 doses PK metrics: AUC0-24, Cmax and AURC0-24
Day 3 doses PK metrics: AUCo-24,ss (to reflect safety) and AURCo-24,Day3 (to reflect efficacy).
Concentration-time profiles of Cthrough concentrations were provided to assess reaching of steady-state. High Cthrough variability was observed as usual for very low plasma concentration levels at time points beyond 5 times the plasma elimination half-life. This is not unexpected as the elimination half-life is approximately 1 hr and so, by the 12-hour interval, more than 95% of the absorbed dose is eliminated. In fact, the majority of subjects showed Cthrough levels below the limit of quantitation. Hence, a steady state based on similar Cthrough levels cannot be established as the pharmacokinetics of the product at the 12-hour dosage interval were essentially repeat single doses.
According to the Study Protocol, the AUCo-24h, Cmax and AURCo-24h for Day 1 and AUCo -24h,ss and AURCo -24h,Day3 for Day 3 for furazidin were used to assess equivalence
between both tested formulations. The results confirm that the 90% confidence intervals for Test to Comparator ratios of the geometric least squares means for above mentioned PK parameters were not within the bioequivalence acceptance range of 80.00% to 125.00%.
The results further confirmed that the exposure to the Test formulation was higher in terms of extent and intensity than exposure to the Comparator formulation both in plasma and urine.
Safety Results: Seven (7) subjects experienced a total of sixteen (16) moderate adverse events (AE). In total, four (4) adverse events were considered related to the oral administration of the Test product (i.e. the episodes of moderate headache), and six (6) adverse events (i.e. also episodes of moderate headache) were considered related to the oral administration of Comparator product.
Table 17. Pharmacokinetic parameters of furazidin in plasma after single dose administration (Day 1)
AUCo-24h The area under the plasma concentration-time curve calculated from time zero until 24 hours Cmax The maximum plasma concentration observed (ng/mL) tmax The time of maximum plasma drug concentration (h) ti/2 The elimination half-life associated with the terminal slope of a semi-logarithmic plasma concentration-time curve or the urine excretion rate-time curve (h), ti/2= ln(2)/ z a arithmetic mean ± SD b In-transformed values c median, range
Table 18. Pharmacokinetic parameters of furazidin in plasma after multiple-dose dose administration (Day 3)
AUCo-24h,ss The area under the plasma concentration-time curve calculated from time zero until 24 hours Cmax,ss The maximum plasma concentration observed (ng/mL)
AUCO-T Area under the plasma concentration versus time curve (ng h/mL) calculated by the linear trapezoidal rule from sampling time zero to sampling time r = 12 h (Treatment A) or r = 8 h (Treatment B).
AUCO-T, ss Area under the plasma concentration versus time curve (ng h/mL) calculated by the linear trapezoidal rule from sampling time zero to sampling time r = 12 h (Treatment A) or r = 8 h (Treatment B) in steady-state. tmax,ss The time of maximum plasma drug concentration (h)
The elimination half-life associated with the terminal slope of a semi-logarithmic plasma concentration- ,ss time curve or the urine excretion rate-time curve (h), ti/2= ln(2)/ z
Cmin,ss arithmetic mean ± SD a In-transformed values b median, range c median, range
Fig. 3 shows the pharmacokinetic profile of means (N=29) in plasma (A=Test product,
B=Comparator). Fig. 4 shows the pharmacokinetic profile of means (N=29) in urine (A=Test product,
B=Comparator).
Table 19. Pharmacokinetic parameters of furazidin in urine after single and multiple-dose administration
AURCo-24h Area under the urine excretion rate-time curve from sampling time zero to time 24 h (pg)
AURCo -24h,Day3 Area under the urine excretion rate-time curve from sampling time zero to time 24 h after multiple dose administration (pg)
Aeo-24h Cumulative urinary excretion of unchanged drug from sampling time zero to time 24 h calculated as Sum of Volume x Concentration increments (pg)
AeO-24h,Day3 Cumulative urinary excretion of unchanged drug from sampling time zero to time 24 h calculated as Sum of Volume x Concentration increments after multiple dose administration (pg)
Rmax The maximum rate of drug excretion observed (pg/h)
Rmax,Day3 the maximum urinary excretion rate observed after multiple dose administration (pg/h) a arithmetic mean ± SD
In-transformed values
Conclusion: No accumulation was observed after multiple dosing and steady state was not confirmed for Test product after 3 days of dosing as expected by the short elimination halflife and the associated kinetics of repeat single doses. Bioavailability of Test product was higher after single and multiple dose administration compared to the Comparator product.
Summary PK: Furazidin is mainly absorbed in the upper part of the small intestine. Bioavailability was found 1.9-fold higher after high-protein meal than under fasting conditions. After single oral administration of the furazidin prolonged-release tablet, 200 mg according to the present invention to healthy volunteers in fed conditions (high-protein meal), the peak serum concentration 353.1±122.5 ng/mL (Cmax) was reached within approx. 2.5 hour (tmax), AUCo-24 reached 1404.1±392.8 ng*h/mL. Following administration of the furazidin prolonged-release tablet 200 mg in a fasting state, the maximum serum concentration 256.7±87.3 ng/mL (Cmax) was reached within 2 hours (tmax). After multiple dose oral administration of furazidin prolonged-release tablet, 200 mg to the healthy volunteers for 3 days (twice a day, 12 hours apart), peak plasma concentrations were reached at about 51 hours following administration under fed conditions (high-protein meal). Cmax,ss and AUCo-24, ss reached 516.4±149.3 ng/mL and 3498.1±932.2 ng*h/mL, respectively.
Claims
1. A prolonged-release pharmaceutical composition for oral administration, comprising: a) an immediate release component, comprising furazidin and one or more pharmaceutically acceptable excipients; and b) a modified-release component, comprising furazidin, a controlled-release agent, and one or more pharmaceutically acceptable excipients.
2. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is a single dosage form in the form of a tablet, in which the immediate release component a) forms a first layer, the modified-release component b) forms a second layer, and the first layer at least partially covers the surface of the second layer, and, preferably, the tablet is a bilayer tablet.
3. The pharmaceutical composition according to claim 1 or 2, wherein the immediate release component a) is contained as granulates, and the modified-release component b) is contained as granulates, wherein the immediate release component a) and/or the modified-release component b) optionally also contain an extragranular fraction comprising one or more of a lubricant, a filler, an absorbent and a glidant.
4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the pharmaceutical composition is a single dosage form comprising, in total, 150 to 250 mg of furazidin, preferably 180 to 220 mg of furazidin, and more preferably 200 mg of furazidin.
5. The pharmaceutical composition according to claim 4, wherein the immediate release component a) comprises 35 to 55 mg of furazidin, and the modified-release component b) comprises 145 to 165 mg of furazidin; and, preferably, the immediate release component a) comprises 45 to 55 mg of furazidin, and the modified-release component b) comprises 145 to 155 mg of furazidin; and, more preferably, the immediate release component a) comprises 50 mg of furazidin, and the modified-release component b) comprises 150 mg of furazidin.
59
6. The pharmaceutical composition according to any one of claims 1 to 5, wherein the modified-release component b) comprises 10 to 40 wt.% of the controlled-release agent, preferably 10 to 35 wt.% and more preferably 20 to 30 wt.% of the controlled-release agent, based on the total weight of the modified-release component b).
7. The pharmaceutical composition according to any one of claims 1 to 6, wherein, in a matrix of the modified-release component b), the controlled-release agent comprises at least one pH-independent polymer.
8. The pharmaceutical composition according to claim 7, wherein the pH-independent polymer is at least one selected from the group consisting of hydroxypropylmethylcellulose (HMPC), hydroxyethylcellulose (HEC), hydroxypropylcellulose, methylcellulose (MC), xanthan gum, sodium carboxymethylcellulose, non-ionic poly(ethylene oxide), copovidone (vinylpyrrolidone-vinyl acetate copolymer) and any combination thereof.
9. The pharmaceutical composition according to any one of claims 1 to 8, wherein the immediate release component a) comprises, as the at least one excipient, at least one of a filler, a disintegrant, a binder, a lubricant, a glidant and any combination thereof, preferably, the immediate release component a) comprises 10 to 50 wt.% of a filler, 0.5 to 6 wt.% of a disintegrant, 1.4 to 1.7 wt.% of a glidant, 2 to 4 wt.% of a lubricant, and, optionally, 0.4 to 5 wt.% of a binder, based on the total weight of the immediate release component a).
10. The pharmaceutical composition according to any one of claims 1 to 9, wherein the modified-release component b) comprises, as the at least one excipient, at least one of a filler, a disintegrant, a binder, a lubricant, a glidant and any combination thereof, preferably, the modified-release component b) comprises 10 to 40 wt.% of the controlled-release agent and 10 to 45 wt.% of a filler, 0.3 to 5 wt.% of a disintegrant, 0.4 to 5 wt.% of a binder, 0.5 to 2 wt.% of a lubricant, and, optionally, up to 1.3 wt.% of a glidant, based on the total weight of the modified-release component b).
11. The pharmaceutical composition according to any one of claims 1 to 10, wherein the pharmaceutical composition is a single dosage form and has an in vitro dissolution rate of
60 furazidin of 10 to 40 wt.%, preferably 10 to 30 %, within 1 h, 40 to 65 wt.% within 6 h and above 80 wt.% within 14 h, based on the total furazidin content of the single dosage form, as determined by using European Pharmacopoeia edition 10 Apparatus Baskets “1” in 1000 ml volume of phosphate buffer solution of pH=6.8 with the addition of 2.5% CTAB (hexadecyltrimethylammonium bromide) at 37.0°C±0.5°C and 100 rpm.
12. A pharmaceutical composition as defined in any one of claims 1 to 11 for use in a method of treatment of a urinary tract infection.
13. The pharmaceutical composition for use according to claim 12, wherein the urinary tract infection is an acute or recurrent uncomplicated urinary tract infection.
14. The pharmaceutical composition for use according to claim 12 or 13, wherein the pharmaceutical composition is a single dosage form, which is administered orally two times daily, and preferably 11 to 13 hours apart, and more preferably 12 hours apart.
15. The pharmaceutical composition for use according to any one of claims 12 to 14, wherein oral administration of one single dosage form of the pharmaceutical composition provides a maximum plasma concentration of furazidin (Cmax) of 353.1±122.5 ng/mL after tmax of 2.5±0.5 hours after administration, and an area under the plasma concentration-time curve from time zero to 24 hours (AUC0-24) of 1404.1±392.8 ng h/mL, as determined by human PK studies.
16. The pharmaceutical composition for use according to any one of claims 12 to 15, wherein oral administration of a single dosage form of the pharmaceutical composition twice a day and 12 hours apart provides after 3 days a maximum plasma concentration in steady state (Cmax,ss) of furazidin of 516.4±149.3 ng/mL and an area under the plasma concentrationtime curve from time zero to 24 hours in steady state (AUCo-24,ss) of 3498. 1±932.2 ng h/mL, as determined by human PK studies.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21153203.1A EP4032530A1 (en) | 2021-01-25 | 2021-01-25 | Prolonged-release furazidin composition |
PCT/EP2022/051486 WO2022157357A1 (en) | 2021-01-25 | 2022-01-24 | Prolonged-release furazidin composition |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4281048A1 true EP4281048A1 (en) | 2023-11-29 |
Family
ID=74236033
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21153203.1A Pending EP4032530A1 (en) | 2021-01-25 | 2021-01-25 | Prolonged-release furazidin composition |
EP22702430.4A Pending EP4281048A1 (en) | 2021-01-25 | 2022-01-24 | Prolonged-release furazidin composition |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21153203.1A Pending EP4032530A1 (en) | 2021-01-25 | 2021-01-25 | Prolonged-release furazidin composition |
Country Status (2)
Country | Link |
---|---|
EP (2) | EP4032530A1 (en) |
WO (1) | WO2022157357A1 (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3643325B1 (en) * | 2016-10-10 | 2024-04-10 | Przedsiebiorstwo Produkcji Farmaceutycznej Hasco-Lek S.A. | A composition comprising furazidin and a method of its manufacturing |
-
2021
- 2021-01-25 EP EP21153203.1A patent/EP4032530A1/en active Pending
-
2022
- 2022-01-24 EP EP22702430.4A patent/EP4281048A1/en active Pending
- 2022-01-24 WO PCT/EP2022/051486 patent/WO2022157357A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2022157357A1 (en) | 2022-07-28 |
EP4032530A1 (en) | 2022-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6955821B2 (en) | Sustained release formulations of guaifenesin and additional drug ingredients | |
US6756057B2 (en) | Amoxicillin and potassium clavulanate dosage form | |
CN106943355B (en) | Pharmaceutical composition | |
US20090281153A1 (en) | Extended Release Tablet Formulation Containing Pramipexole or a Pharmaceutically Acceptable Salt Thereof | |
US20020128251A1 (en) | Novel formulation | |
EP2448561B1 (en) | Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application | |
US20050158380A1 (en) | Sustained release oral dosage forms of gabapentin | |
US20050053658A1 (en) | Extended release systems for macrolide antibiotics | |
WO2004019901A2 (en) | Sustained release pharmaceutical composition | |
WO2006123213A1 (en) | Modified release formulations of gliclazide | |
CZ20022883A3 (en) | Formulation in the form of a tablet | |
WO2009027786A2 (en) | Matrix dosage forms of varenicline | |
US20060002997A1 (en) | Nitrofurantoin controlled release dosage form | |
US20060147530A1 (en) | Sustained release compositions containing alfuzosin | |
WO2005092293A1 (en) | Formulations of metformin | |
EP4032530A1 (en) | Prolonged-release furazidin composition | |
WO2003011256A1 (en) | Oral controlled release pharmaceutical composition of a prokinetic agent | |
AU2005235237A1 (en) | Clarithromycin extended release formulation | |
EP2392318A1 (en) | A pharmaceutical controlled release composition of losartan | |
CA2893480C (en) | Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide | |
KR102409102B1 (en) | pharmaceutical composition | |
US20150224056A1 (en) | Pharmaceutical compositions of ibuprofen and famotidine | |
JP2021518424A (en) | Oral tablet composition of various doses of lenalidomide | |
US20230201123A1 (en) | Pharmaceutical composition | |
WO2021160700A1 (en) | Composition comprising ramipril and indapamide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20230822 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |